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ABSTRACT 
Prostate cancer is the most common cancer in men and the second leading cause of 
cancer-related death in western world. Typically, the treatment of advanced and metastatic 
prostate cancer consists of castration therapy, which suppresses the development of the 
disease for 2 years in average. Virtually all patients, undergoing androgen deprivation 
therapy eventually develop castration-resistant prostate cancer. Currently, only taxane 
class of drugs has been proven to provide short survival advantage in patients with 
castration-resistant prostate cancer. This form of the disease is the cause of significant 
morbidity, resulting in long periods of gradual deterioration of patients’ condition, pain 
related to local extension of the tumour and distant metastases, renal failure due to the 
invasion into the ureters etc. 
Castration resistance allows prostate tumours to progress despite androgen 
deprivation. Several mechanisms have been described, outlining the nature of molecular 
pathways, employed by prostate cancer cells in order to proliferate and migrate in low 
androgen environment. Hormone-sensitive prostate cancer cells rely on androgens for their 
growth needs with androgens acting through the androgen receptor (AR). In castration-
resistant prostate cancer AR can be activated by reduced concentrations of androgens, AR 
antagonists, protein kinases or bypassed altogether. Detailed knowledge of these processes 
should allow better understanding of molecular patterns, driving the progression of 
prostate cancer and, ultimately, could lead to the development of novel molecular targeted 
therapies. 
Molecular pathways, implicated in the development of castration-resistant prostate 
cancer frequently show cross-talk, resulting in the ability of cancer cells to adapt to 
changing microenvironment. Inhibiting the proteins, facilitating these cross-talks provides 
an attractive targeting mechanism. Src family of non-receptor tyrosine kinases (SFK) 
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represent proteins involved in the development of various solid malignancies, including 
prostate cancer. These proteins are often found on the cross-roads of intracellular 
pathways, integrating molecular systems into complex signalling networks. SFK interact 
with receptor tyrosine kinases, G-protein coupled receptors, motility and adhesion factors 
and, thus, influence multiple cell functions. In prostate cancer, SFK have been 
demonstrated to form complexes with AR, activating AR by means of tyrosine 
phosphorylation. 
SFK inhibitory compounds have been developed and are now in Phase II clinical 
trial in patients with castration-resistant prostate cancer. However, there is considerable 
lack of data regarding the role of SFK expression and activation in prostate cancer in 
clinical settings. In this thesis, we studied the role of SFK in prostate cancer using matched 
paired prostate cancer samples, taken from patients prior to castration therapy being 
administered and following the development of castration resistance. Using paired tissue 
specimens allows following molecular changes through the natural history of the disease 
and correlating these changes with various clinical parameters. We also conducted in vitro 
experiments, employing hormone-sensitive LNCaP cell line and its counterpart, castration-
resistant LNCaP-SDM cell line, developed by gradual withdrawal of androgens from the 
culture medium. 
Our main finding is that in a subgroup of prostate cancer patients, the increase in 
SFK activity in the transition of prostate cancer from hormone-sensitive to castration-
resistant state is associated with significant decrease in survival (p<0.0001). Furthermore, 
the presence of bone metastases in patients with castration-resistant prostate cancer was 
associated with higher SFK activity in prostate tissue specimens. Our in vitro experiments 
have demonstrated that in prostate cancer the relationship between SFK and AR are 
important as androgen deprivation resulted in significant reduction in SFK activity. Using 
SFK inhibitor dasatinib, we have shown that in prostate cancer cell lines, SFK activity was 
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inhibited at low nanomolar concentrations. Inhibition of SFK activity was accompanied by 
the inhibition of downstream protein FAK at Src-specific phsophorylation site. Although 
the treatment with SFK inhibitor suppressed migration of both LNCaP and LNCaP-SDM 
cell lines, only proliferation of LNCaP-SDM cell was affected by dasatinib. 
Taken together, our date suggests that SFK inhibitors may have a role in the 
treatment of castration-resistant prostate cancer. However, important considerations should 
be given to the molecular heterogeneity of prostate cancer in order to improve the 
outcomes of clinical trials and the response to treatment. There is considerable evidence 
that SFK inhibitors suppress prostate cancer cells migration and future studies will 
hopefully further clarify their role in cancer cells proliferation. 
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1.1 SFK in Cancer 
 
1.1.1           Discovery and Evolution of Knowledge 
 
Almost one hundred years passed since the discovery of a sarcoma virus by Peyton 
Rous at the Rockefeller Institute in New York. He studied tumours developed by chickens 
of Plymouth Rock breed, which on microscopic examination were found to be sarcomas. 
When the tumours were removed, homogenised and filtered, Rous was surprised to 
discover that if the filtrate was injected into another chicken of the same species, a similar 
tumour started to grow. Thus, Rous concluded that the malignancy was caused by a 
filterable agent and published the findings in the Journal of Experimental Medicine in 
1911 (1).  However, due to the controversy surrounding the issue of cancer being caused 
by a known agent it was not until 1950s when a similar strain of virus was found to induce 
sarcoma in mammals that intensive research on the topic resumed. Several decades later 
light was shed on the retroviral features of Rous Sarcoma Virus (RSV), as it was then 
called, and its genetic makeup. Finally, the transforming gene v-src, responsible for the 
malignant properties of RSV was identified and sequenced in the laboratory of Mike 
Bishop in late 1970s (2). 
In 1969 Huebner and Todaro postulated that the cells of vertebrates contain viral 
genes or oncogenes that are under certain circumstances transformed and, when activated, 
could stimulate the cells to behave in a malignant fashion (3). However, it was later found 
that normal cellular genes when induced by viruses, could gain malignant potential and, 
therefore, they are termed ‘proto-oncogenes’. One of the first proto-oncogenes identified 
by Bishop and Varmus was c-src (4), cellular equivalent of v-src, this discovery earned 
them the Nobel Prize. The product of c-src gene, c-Src protein was found to possess 
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protein tyrosine kinase activity and, furthermore, c-Src itself was demonstrated to be 
phosphorylated at tyrosine residues (5). Two decades later and a considerable amount of 
work that followed gave insight into the complex modular structure of c-Src protein, which 
was shown to consist of several domains involved in various inter- and intramolecular 
interactions (6). It was discovered that c-Src can switch between inactive and active state 
depending on which of two tyrosine residues are phosphorylated, tyrosine Y419, located on 
the carboxyl terminal of the protein or tyrosine Y527 of the amino-terminal (7;8).  
Following identification of c-Src as a tyrosine kinase, multiple substrates and downstream 
signalling proteins were identified, including focal adhesion kinase (FAK) (9), mitogen-
activated protein kinase (MAPK) (10), phosphatidylinositol 3-kinase (PI3K) (11) etc. As a 
result of multiple molecular interactions c-Src (later in the text referred to as Src) plays a 
role in multiple cellular functions that include proliferation, adhesion, migration and cell 
cycle progression (12). 
 
1.1.2           Structure and Activation 
 
Nine non-receptor protein kinases: Src, Fyn, Yes, Blk, Yrk, Fgr, Hck, Lck and Lyn 
with similar structural features to Src, make up Src family kinases. Src, Fyn and Yes are 
ubiquitously expressed in all tissues whereas the expression of others may differ (13). So 
far, four SFK members have been implicated in the development of prostate cancer in its 
progression to hormone independence: Src, Lyn, Fyn and Fgr (14-17). Due to the 
similarity of the amino acid sequences and, as a result, cross-reactivity of antibodies, all 
family members are usually studied together and only now we are beginning to unravel the 
functional differences between them (18;19). Separate knockout of Src and Lyn by siRNA 
in PC3-derived prostate cancer cell lines revealed that these SFK members may play 
different roles in prostate cancer. While inhibition of Src affected primarily migratory 
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properties of prostate cancer cells, suppression of Lyn was responsible for inhibition of 
proliferation (18). 
High resolution crystallographic analysis revealed complex 3-dimentional structure 
of Src protein, which is a prototype of other family members (20). Src consists of four 
domains (Figure 1): a unique to each family member domain, two Src homology (SH) 
domains SH3 and SH2, kinase domain, containing tyrosine Y419 (avian equivalent - 
tyrosine Y416) and carboxy-terminal negative regulatory domain, containing tyrosine Y527, 
which is mutated in v-Src making it constitutively activated. In addition, the molecule 
contains amino-terminal myristoylation sequences necessary for the association of the 
protein with cellular membranes. 
Several mechanisms of Src activation have been described. When tyrosine Y527 of 
the negative regulatory domain is phosphorylated by c-Src kinase (Csk) the molecule is 
folded preventing its’ association with substrates (21). Following tyrosine Y527 
dephosphorylation by protein tyrosine phosphatises, Src becomes autophosphorylated at 
tyrosine Y419 allowing the protein to unfold and assume catalytically active conformation.  
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Figure 1. The domain structure of c-Src and v-Src proteins. Adapted from Frame 
(13). For comparison, viral (v-Src) and cellular (c-Src) structures are presented. Src 
molecule is made up of several domains: U – unique to each family member domain 
with amino-terminal myristoylation sequences (M), Src homology 2 and 3 domains 
(SH2 and SH3), kinase domain with tyrosine Y419 as an activation marker (aviav 
equivalent tyrosine Y416) and negative regulatory domain (R), containing tyrosine 
Y530 (avian equivalent tyrosine Y527), which is absent in viral Src making it 
constitutively activated. 
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Once Src unfolds, it becomes available for the interaction with various docking 
substrates that, in turn, can activate Src by intra-molecular displacement. Another 
mechanism of Src activation, called intracellular targeting, involves physical transfer of 
inactive Src from peri-nuclear region to the cell membrane, where it forms complexes with 
other proteins regulating various important cell functions including adhesion, invasion and 
migration (22). Finally, other mechanisms regulating Src function in cancers include 
increased expression, naturally occurring mutations (23) as well as post-translational 
events e.g. altered ubiquitin-dependent degradation (24). 
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Figure 2. Mechanism of Src activation. Adapted from Martin (25). In its basal state, 
Src molecule is kept folded by intramolecular constrains. Activation involves 
phosphorylation of tyrosine Y416 in the kinase domain and dephosphorylation of 
tyrosine Y527 in the negative regulatory domain, allowing the molecule to unfold and 
assume catalytically active conformation. 
 
Basal 
activity 
Activated 
kinase 
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1.1.3 Cellular Processes Controlled by SFK 
 
Involvement of SFK in multiple intracellular molecular networks explains the role 
SFK play in various cell functions. Although considerable evidence implicating SFK in 
adhesion, migration and invasion exists, their role in proliferation is less well determined. 
Cell movement is a complex well coordinated process involving weakening of cell-cell 
bonds, formation of protrusions and their attachment to extracellular matrix (ECM) in the 
leading part of the cell, cytoskeletal reorganisation propagating the body of the cell 
forward and detachment of the cell at the rear end. Src is a key component in adherence 
junctions and focal adhesion complexes, regulating cells motility by disrupting cell-cell 
contacts and increasing focal adhesions turnover (26). Regulation of invasive properties of 
cancer cells by Src is achieved by inhibition of cadherins (proteins stabilising cell-cell 
junctions), increasing degradation of cadherin complexes and regulation of matrix 
metalloproteinases (MMP) (27;28).  
Tumour growth depends on the balance between proliferation and apoptosis and 
SFK may play a role in both processes. Following stimulation by growth factors, Src 
becomes activated integrating signals into proliferative and anti-apoptotic cascades e.g. 
Ras/MAPK and PI3K/Akt. In addition, other important processes are influenced by Src, in 
particular induction of DNA synthesis and cell cycle progression. Thus, although the role 
of Src in cancer cell proliferation remains controversial, SFKs may regulate different 
stages of tumour growth in different tissues and the end result probably represents the 
cumulative effect of these processes (12). 
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1.2 SFK Molecular Interactions in Prostate Cancer 
 
Prostate cancer is the most common malignancy in men living in the Western world 
and the second, after lung cancer, leading cause of cancer-related death. The number of 
new prostate cancer cases in the US in 2009 is projected to be in the region of 192,280, 
which will make up 25% of all new cancer cases (29). Approximately 27,360 prostate 
cancer patients will die in 2009 in the US, with only the number of deaths due to lung and 
bronchial cancer exceeding prostate cancer-related mortality. In the UK, 35,515 patients 
were diagnosed with prostate cancer in 2006 and in 2007 there were 10,239 deaths related 
to prostate cancer (30). Prostate cancer incidence has racial and geographical variations 
with men of african-american origin suffering from the highest rates of the disease, 
whereas east-asian men have the lowest incidence.  
When prostate cancer is suspected on clinical examination or following prostate 
specific antigen (PSA) testing, the trans-rectal ultrasound scan (TRUS) biopsy of the 
prostate is performed and histological assessment of prostate tissue is conducted to 
confirm the diagnosis. The management depends on the individual patients’ condition, co-
morbidities as well as the grade and the stage of prostate cancer. Organ-confined disease 
can be treated with radical surgery or radiotherapy, whereas locally-advanced or metastatic 
disease is managed using androgen-deprivation therapy, which is also used in neo-adjuvant 
settings. Most of the patients, to whom the radical treatment is administered, are cured, 
although approximately a third develop prostate cancer relapse and, therefore, require 
androgen-deprivation therapy. 
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1.2.1  Castration Resistance in Prostate Cancer  
 
Androgen-deprivation therapy has been the mainstay of locally advanced and 
metastatic prostate cancer treatment over the last five decades (31). The concept of this 
treatment is based on the fact that androgens play a crucial role in promoting proliferation 
and migration of prostate cancer cells while inhibiting apoptosis. Androgen-deprivation 
therapy can be administered in the form of surgical castration, gonadotropin-releasing 
hormone (GnRH) receptor agonists or androgen receptor (AR) antagonists. However, the 
effect of androgen ablation only lasts for 2 years in average, following which prostate 
cancer patients invariably develop castration resistant prostate cancer (CRPC). Currently, 
there are no effective therapies for this type of prostate cancer. 
Several mechanisms, traditionally described as pathways, have been implicated in 
the development of CRPC (32). Prostate cancer cells may adapt to a low level androgen 
environment by increasing the expression of AR, increasing sensitivity of AR to androgens 
and stimulation of intracellular conversion of testosterone to a significantly more potent 
androgen dihydrotestosterone by 5α-reductase (33). This mechanism is frequently referred 
to as the hypersensitive pathway. AR could also become susceptible to activation by 
various non-androgen steroids and androgen antagonists (promiscuous pathway), non-
steroidal molecules, such as growth factors (outlaw pathway) or prostate cancer cells may 
develop molecular cascades bypassing AR altogether (bypass pathway) (34-36). Finally, 
prostate tumours are thought to contain stem cells (previously known as lurker cells) with 
the potential to differentiate into heterogeneous population, frequently found in CRPC 
specimens, whilst maintaining self-renewal (37).  
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Figure 3. Mechanisms involved in the development of CRPC. Adapted from  
Feldman et al. (32). Pathways involved in the development of CRPC are presented. 
Hypersensitive pathway – increase in sensitivity to low concentration of androgens by 
amplification of AR, promiscuous pathway – AR is stimulated by corticosteroids, 
anti-androgens etc., outlaw pathway – AR is activated via different other routes e.g. 
phosphorylation by tyrosine kinases and bypass pathway, where AR is bypassed 
altogether. Lurker cells represent a population of undifferentiated (stem) cells that 
are thought to develop into cancer, already adapted to low androgen environment. 
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1.2.2 Interaction of Androgen Receptor with SFK 
 
In prostate cancer AR signalling typically involves binding of androgens to the 
receptor located in the cytoplasm, dimerisation of the receptor, its translocation to the 
nucleus and activation of the transcriptional apparatus resulting in multiple biological 
events (38).  
Although previously the role of the AR in prostate cancer had been regarded 
primarily as a ligand-dependent transcription factor, recently there has been much interest 
in studying non-genotropic properties of the receptor. AR could be integrated into the 
network of signalling pathways by forming physical association with tyrosine kinases, 
including Src, or responding to growth factors stimulation (39). Proline-rich sequences of 
AR have been shown to display affinity for SH3 domain of Src, so that the resulting 
complexes release Src intra-molecular constrains, activating the tyrosine kinase. Androgen 
stimulation acted as a trigger for the AR-Src complex formation, which was followed by 
activation of Src/Raf-1/Erk-2 pathway and, as a result, the increase in prostate cancer cells 
proliferation. Application of androgen antagonists, expression of Src lacking SH3 domain 
and treatment with Src inhibitor prevented androgen stimulated S-phase entry resulting in 
cell-cycle arrest (40).  
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Figure 4. Action of androgen receptor in prostate cancer. Adapted from Suzuki et al. 
(38). Testosterone, converted to DHT by 5α-reductase, stimulates AR located in 
cytoplasm in complexes with Hsp. Dimerised AR then translocates into the nucleus, 
where it form complexes with co-factors (ARA) in order to activate androgen 
responsive elements (ARE) regions of DNA. The end result – the increase in prostate 
cancer cells proliferation and production of various proteins, including PSA. 
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Differentially expressed in ovarian cancer-2/disabled 2 (DOC-2/DAB 2) has 
originally been discovered in ovarian cancer as a candidate tumour suppressor gene (41). 
The protein contains proline-rich sequences interacting with Src and Fgr, SFK members, 
containing SH3 domain. This interaction was demonstrated to inhibit SFK activity due to 
conformational changes, locking SFK molecules in catalytically inactive conformation 
(42). There is inverse relationship between AR expression in normal prostatic epithelium 
and prostate cancer and DOC-2/DAB 2 expression. It is possible to increase proliferation 
of CRPC cells expressing AR by knocking out DOC-2/DAB 2 with siRNA. Tumour 
suppression properties of DOC-2/DAB 2 are thought to be due to the ability of this protein 
to disrupt AR/Src complex formation and inactivation of Erk and Akt. Non-genomic action 
of DOC-2/DAB 2 was further confirmed by the fact that AR transcriptional activity was 
not affected (43). 
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Figure 5. DOC-2/DAB 2 prevents AR/Src complex formation. Adapted from Zhoul et 
al. (43). AR interacts with activated Src (pSrcY416) and formation of AR/Src 
complexes leads to downstream Erk activation. DOC-2/DAB2 functions as a negative 
regulator by displacing AR from the complexes with Src, thus preventing Erk 
activation and, as a result, decreasing prostate cancer cells proliferation. 
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Apart from androgens, growth factors and cytokines have the potential to activate 
SFK and stimulate AR-Src complex formation in prostate cancer cells. Epidermal growth 
factor (EGF) acting through epidermal growth factor receptor (EGFR) has been shown to 
activate Src in prostate cancer cells, experiencing acute androgen withdrawal by triggering 
AR-Src complex formation. Resulting DNA synthesis and cytoskeletal changes were 
abrogated by treatment with androgen antagonists, suggesting an important role of the 
relationship between AR and Src in prostate cancer cells biology (44;45). Androgen 
independent growth and cell migration, stimulated by Interleukin-8 (IL-8) signalling may 
involve trans-activation of AR by Src as both Src inhibitors and AR antagonists have been 
demonstrated to down-regulate these biological processes (46).  
Castration resistant phenotype has been associated with constitutive activation of 
Src/MAPK pathway. This was demonstrated in vitro by the increased [(3)H]thymidine 
incorporation and the increased resistance to apoptosis. Furthermore, Src/MAPK activation 
in androgen-sensitive cells can be triggered by dihydrotestosterone (DHT), potent activator 
of AR (47). Therefore, AR could regulate transcription either following ligand binding, or 
by becoming involved in complexes with tyrosine kinases e.g. Src.  
Tyrosine phosphorylation is thought to be an important mechanism of modulation of 
AR activity. Many biological processes involving AR, including cytoplasm to nuclear 
translocation and transcription, are regulated by tyrosine phosphorylation (34;48;49). Due 
to rapid and transient nature of this process, identification of AR phosphorylation sites 
specific to various tyrosine kinases has proved difficult. Guo et al. found significant 
correlation between AR and Src activation in human prostate tumours and proposed 
tyrosine Y534 as a Src-specific phosphorylation site. These findings suggest that androgen 
deprivation therapy may result in Src activation by growth factors, which can then 
stimulate AR activity as a potential hormone escape mechanism (50). 
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1.2.3 G-protein coupled receptors and SFK 
 
Guanosine phosphate binding protein coupled receptors (GPCR) have been 
implicated in the proliferation and survival of prostate cancer cells. Conventionally, the 
heptahelical receptor is made up of seven membrane-spanning regions. Following ligand 
binding, the receptor interacts with a heterotrimeric G-protein, consisting of three subunits: 
α, β and γ. This leads to α subunit, which carries guanosine diphosphate (GDP), to 
dissociate from the complex, followed by GDP becoming converted to GTP (51). Thus, 
the process creates second messengers that activate many intracellular signalling cascades. 
Although it was previously thought that GPCRs were mainly involved in the short –
term regulation of intermediary metabolism and neurotransmission, it has recently become 
known that these receptors can influence cell growth and differentiation in a variety of 
clinical conditions including benign prostatic hypertrophy and prostate cancer. SFK play 
key roles in integrating signals emanating from GPCRs into proliferative and anti-apototic 
molecular networks (52). The mechanisms of SFK-GPCR interaction are complex and 
include direct binding through SH2 and SH3 homology domains, association with 
heterotrimeric G-proteins and cross-talk with receptor protein kinases and focal adhesion 
complexes (53). 
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 Figure 6. Activation model of GPCRs. Adapted from Daaka (51). In inactive state, 
GPCRs form complexes with G-proteins, consisting of α, β and γ subunits. Ligand (L) 
binding leads to phosphorylation of GDP on α subunit to GTP and dissociation of α 
subunit from the complex. 
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Formation of complexes between GPCRs and SFK as the mechanism of cooperation 
and mutual activation has been best described for β3 adrenoreceptor (54). This process is 
mediated through proline-rich regions in the third intacellular loop and carboxyl terminus 
of the receptor containing consensus sequences for SH3 domain of Src. Thus, complex 
formation is necessary for downstream MAPK signalling and point mutations, induced in 
these regions were shown to prevent Src co-immunoprecipitation and MAPK activation. 
Src may, in turn activate GPCRs by tyrosine phosphorylation and tyrosine Y305 has been 
suggested as a Src-specific phosphorylation site on β2 adrenoreceptor (55).  
Several lines of evidence indicate that Src can be activated directly by heterotrimeric 
G-proteins. Direct binding of Gα subunit to inactive Src phosphorylated at tyrosine Y530 
resulted in disruption of intra-molecular bonds and Src activation by intra-molecular 
displacement mechanism (56).  Once again, this interaction appears to be mutual so that G-
proteins are phosphorylated by Src, resulting in the increase of G-protein activity. Gα 
subunit became phosphorylated and hydrolysis of phosphatidyl inositol increased 
following stimulation of fibroblasts transformed by avian v-Src (constitutively active form 
of the protein) with endothelin-1. Furthermore, these processes were disrupted by 
application of Src inhibitor PP2 (57). 
Stimulated GPCRs may produce downstream signals, resembling the signals 
emanating from receptor tyrosine kinases. This is due to GPCRs involvement in the 
extensive cross-talk with receptor tyrosine kinases and SFK may play a role in these 
processes. Although the exact nature of this interaction is unknown, several mechanisms 
have been described. One of them, called ectodomain shedding, involves the generation of 
growth factors from transmembrane precursors and their release into the extracellular 
milieu where they can interact with the receptors (58). Precursors of tyrosine kinases 
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agonists are insoluble and, therefore, undergo proteolysis by ADAM family of matrix 
metalloproteinases (MMPs), which are regulated by Src (59). 
Focal adhesions represent protein complexes, consisting of transmembrane receptors 
integrins that interact with extracellular matrix and transmit signals through intracellular 
complexes, where SFK have an important role. Following integrin engagement with 
fibronectin, focal adhesion kinases are recruited to the membrane regions providing 
docking sites for downstream proteins, including Src, leading to the activation of ERK1/2 
pathway (60). GPCRs interact with focal adhesions through activation of focal adhesion 
kinases FAK and Pyk2. This interaction is inhibited by the exposure to the proteins 
containing Arg-Gly-Asp sequences mimicking integrin ligands and by cytochalasin D that 
disrupts actin links (61). The exact nature of the interaction varies, depending on the cell 
type, although Src inhibitors prevented ERK1/2 activation and assembly of Ras activation 
complexes in all cases. 
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Figure 7. GPCR transactivation by RTKs. Adapted from Luttrell et al. (53). Src, 
activated by G- proteins, stimulates ADAM family matrix-metalloproteinases that 
release growth factors from their precursors (e.g. EGF). EGF then binds to EGFR 
that phosphorylates multiple intracellular targets, including Src. 
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Figure 8. GPCRs interaction with focal adhesions. Adapted from Luttrell et al. (53) . 
Ligand-bound  GPCRs release α subunit of G-proteins that activates phospholipase 
Cβ (PLCβ). Resulting increase in intracellular Ca2+ and activation of protein kinase 
C (PKC) leads to activation of Pyk2 or FAK in focal adhesion complexes that 
invariably involve Src.  
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Neuroendocrine (NE) cells represent a type of epithelial cells found in normal 
prostatic tissue and in prostate cancer. They produce various substances that regulate 
growth, differentiation and survival of surrounding cells in autocrine and paracrine 
fashions. Prostate cancer cells acquire features of NE cells in a process called 
neuroendocrine differentiation (NED). NED has been linked with androgen deprivation 
therapy, progression of prostate cancer to the castration-resistant state and poor prognosis 
(62). Several factors, produced by NED cells including bombesin, neurotensin, serotonin 
etc. implicated in the progression of prostate cancer, act through GPCRs (63).  
Bombesin, amphibian tetradecapeptide and its mammalian homolog gastrin-releasing 
peptide (GRP) are the most studied neuropeptides in prostate cancer. Significant 
proportion of patients with castration-resistant prostate cancer have elevated level of GRP 
in their serum (64). Prostate specimens containing invasive prostate cancers have been 
shown to overexpress receptors for bombesin/GRP whereas samples from areas with 
benign prostatic hyperplasia tended to have low level expression of these receptors (65). In 
vitro growth of PC3, castration-resistant prostate cancer cell line, stimulated by bombesin 
was inhibited by application of antibodies against GRP receptor, a member of GPCR 
superfamily (66). Ligand-bound GRP receptor is thought to trigger several transduction 
pathways that include Src. In PC3 cells, this process involves trans-activation of EGFR 
and Ca2+ mobilisation, followed by Src and MAPK activation, eventually leading to 
stimulation of DNA synthesis (67).  Src inhibitors PP1 and PP2 together with reduced 
level of intracellular Ca2+ abolished EGFR transactivation and MAPK phosphorylation. In 
prostate cancer cells expressing AR, Src activated by bombesin may phosphorylate AR in 
androgen-independent manner, thus increasing its translocation to the nucleus and 
assembly of transcriptional complex involving c-Myc (68).  
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Figure 9. AR activation and nuclear translocation triggered by Src. Adapted from 
Desai et al. (68). Src can be activated by neuropeptides, growth factors and 
chemotactik substances. Activated Src stimulates AR dimerisation and nuclear 
translocation, where AR acts as a transcription factor in complexes with steroid 
receptor co-factors SRC1 and ACTR/AIB1. c-Myc is activated directly by Src 
thereby decreasing apoptosis and increasing polymerase II (Pol II) expression. 
 
45 
 
 
Bombesin and another neuropeptide neurotensin (NT) have been shown to promote 
survival and enhance migratory properties of androgen independent prostate cancer cells 
(69;70). In androgen depleted conditions, neuropeptides are able to circumvent normal AR 
activation pathway, trans-activating reporter genes by prostatic specific antigen (PSA) 
promoter and promoter of androgen responsive element (ARE).  This effect was observed 
only in LNCaP cells expressing AR or PC3 cells that were transfected with a functional 
AR. Activated GPCRs transmit signals through the complexes involving SFK, FAK and 
Etk/BMX non-receptor tyrosin kinases. Furthermore, introduction of dominant negative 
mutant of Src kinase prevented AR activation and its translocation to the nucleus, 
suggesting this mechanism is Src-dependent (71). 
As mentioned earlier, GPCRs exert influence on receptor tyrosin kinases through Src 
to promote growth of castration-resistant prostate cancer cells. Treatment of PC3 cells with 
conditioned culture medium from LNCaP-derived neuroendocrine cells, used as a source 
of NT, resulted in EGFR activation as measured by phosphorylation of Src-specific site at 
tyrosin Y845  (72). EGFR trans-activation was Src dependent as application of catalytic 
inhibitors of both EGFR and Src abolished NT-stimulated DNA synthesis and proliferation 
of PC3 cells. Apart from MAPK, potential downstream proteins conducting the signals 
from EGFR trans-activated by Src included signal transducer and activator of transcription 
5b (STAT5b) (72) and AR co-activator p300 with histone acetyltransferase (HAT) activity 
(73). 
The role of aberrant AR activation by neuropeptides through SFK has recently been 
explored using in vivo model of LNCaP cells, trasfected with vector carrying GRP (74). 
Resulting LNCaP-GRP cell line exhibited castration-resistant properties and enhanced 
migratory abilities, linked with increased SFK activation. Orthotopic implantation of 
LNCaP-GRP cells in castrated nude mice with severe combined immunodeficiency 
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(SCID) produced primary tumour growth and metastases in lymph nodes. Re-cultured 
xenograft cells displayed higher Src activity and AR nuclear translocation in androgen 
depleted medium, compared to native LNCaP cells. Treatment with SFK inhibitor and Src 
knockout by siRNA reduced proliferation and migration in vitro and prevented formation 
of metastatic disease in vivo (75). 
Neuropeptides are inactivated by neutral endopeptidase (NEP), a cell-surface 
enzyme implicated in the development of castration-resistant prostate cancer. NEP 
expression is lost in castratio-resistant PC3, DU145 and TSU-Pr1 prostate cancer cell 
lines, contributing to their invasive properties, in contrast to non-invasive androgen-
sensitive LNCaP prostate cancer cell line that highly express NEP (76). Apart from 
functioning as a main degradation mechanism for neuropeptides, NEP has been linked 
with intracellular transduction pathways that influence cell proliferation, migration, 
invasion and apoptosis (77;78). Intriguingly, SFK members Src and Lyn are thought to 
play opposite roles in regulating these pathways. Activated GPCRs promoted complex 
formation between Src and FAK in focal adhesions, thus stimulating cells migration and 
invasion, whereas Lyn was shown to inhibit these cellular functions by acting as an 
intermediary between NEP and p85 subunit of PI3K, preventing association of PI3K and 
FAK (19). 
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Figure 10. Interaction of NEP with intracellular transduction pathways. Adapted 
from Sumimoto et al. (19). Neutral endopeptidase (NEP) associates with Lyn via 
glycosylphosphatidylinositol-anchored protein (GPI-AP). This leads to the interaction 
between Lyn and p85 subunit of PI3K, preventing association of PI3K with FAK. 
Src, activated by GPCRs, forms complexes with FAK via Src-specific 
phosphorylation site FAKY397. 
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1.2.4 Motility and Adhesion Factors 
 
Oncogenic transformation of normal epithelium into cancer involves acquisition of 
highly motile phenotype, described as epithelial to mesenchymal transition (EMT). The 
changes allow cancer cells to break away from the main tumour mass, which is necessary 
for the local invasion and the development of metastatic disease. Microscopically, the cells 
gain the ability to produce amoeboid protrusions that interact with extracellular matrix 
(ECM) components at the same time destabilising cell-cell contacts (adherence junctions) 
eventually leading to cell detachment, migration or invasion (79). Molecular mechanisms 
involved in EMT involve multiple transduction pathways where SFK frequently play key 
roles (13).  
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Figure 11. Src plays a key role in EMT. Adapted from Frame (13). Activation of Src 
by various mechanisms, including growth factors (e.g. EGF, HGF), leads to the 
acquisition by the normal epithelial cells of highly motile phenotype, resulting in 
epithelial to mesenchymal transition (EMT). 
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Adherence junctions are made up of cadherins (E-cadherin and N-cadherin), trans-
membrane proteins that link the cells by their extracellular components, and catenins (α-, 
β-, γ-, δ- and p120catenin), intracellular proteins providing connections between cadherins 
and actin cytoskeleton. E-cadherin has been described as a suppressor of invasion due to 
its ability to produce stable adherence junctions (80), whereas N-cadherin is thought to be 
part of more dynamic cell-cell contacts and has been linked with aggressive cancer 
phenotype (81). Increased expression of N-cadherin together with reduced expression of 
E-cadherin, described as E-cadherin to N-cadherin (EN) switch, is one of the more 
prominent features of EMT in prostate cancer (82). 
Activated Src destabilises adherens junctions through several mechanisms, including 
phosphorylation of β- and p120catenin that act as anchoring molecules between E-
cadherin and actin, dissociation of E-cadherin and actin, prevention of E-cadherin 
translocation to the membrane and induction of E-cadherin ubiquitylation, recycling and 
degradation through activation of E3-ubiquitin ligases Cbl and Hakai (83).  
Phosphorylation of β-catenin by Src in PC3 cells has been shown to weaken adherence 
junctions by dissociation of β-catenin from E-cadherin, translocation of β-catenin to the 
cytoplasm and nucleus and stimulation of its transcriptional activity. Interestingly, 
expression of α-catenin restricted β-catenin to adherence junctions, thus stabilising cell-
cell contacts, preventing β-catenin nuclear translocation and reducing proliferation. 
Furthermore, by changing its special conformation, α-catenin protected β-catenin from 
phosphorylation by Src (84). 
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Figure 12. α-catenin prevents Src phosphorylation of β-catenin. Adapted from Inge et 
al. (84). Activated Src releases βcatenin from adherence junctions. Translocation of  
β-catenin to the cytoplasm and nucleus results in the increase of its transcriptional 
activity. Overexpression of α-catenin stabilises β-catenin in adherence junctions. 
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Focal adhesions represent complex structures providing cell-ECM contacts where 
more than 50 proteins co-localise and integrate. Facilitating cell movement requires a well 
orchestrated mechanism of focal adhesion assembly at the leading edge of the moving cell, 
accompanied by focal adhesion disassembly at the back and reorganisation of cytoskeleton 
(85). Integrins, trans-membrane proteins, are made up of various combinations of α and β 
subunits, each being sensitive to different ligands and having unique signalling properties. 
Integrins form clusters at the focal adhesions; they provide physical links between ECM 
and the structures of actin cytoskeleton and integrate extracellular signals into intracellular 
transduction cascades, regulating various oncogenic processes in prostate cancer (86). 
Expectedly, due to the necessity of coordination during cell movement, there is extensive 
cross-talk between pathways initiated by growth factor receptors, integrins and cadherins 
(85).  
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Figure 13. Intracellular cascades regulating cell movement. Adapted from Playford et 
al. (85). Src regulates protrusion formation and focal adhesion disassembly, 
participating in biochemical reactions at the front and the rear of the cell. Activated 
Src in complexes with FAK phosphorylates p130cas. This is followed by c-Crk/p130cas 
complex formation and activation of Rac and Cdc42 via translocation of Rac 
activator DOCK1. Activated Rac and Cdc42 promote the development of protrusion 
at the leading edge of the cell by WASP-dependent activation of Arp2/3. At the rear 
of the cell activated Src form complexes with FAK, Erk and calpain 2, leading to 
FAK cleavage and focal adhesion disasemblyfor the purpose of cell detachment ant 
retraction of the tail. 
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Non-receptor tyrosine kinases FAK and SFK are at the heart of the system regulating 
cancer cells motility and EMT (87). Upon integrin engagement, FAK is recruited to the 
focal adhesions and rapidly becomes autophosphorylated at tyrosine Y397, which is high 
affinity Src docking site. Src then induces tyrosine phosphorylation of large number of 
proteins, including FAK itself (Y566, Y577, Y861 and Y925), paxillin (Y118), p130cas (Y410) 
and other substrates (88). Apart from integrins, FAK can be activated by other factors, 
including GPCR ligands (bombesin and IL-8) (46;89) and epidermal growth factor 
receptor (EGFR) through the cross-talk with integrins (90). Activation and recruitment of 
FAK to focal adhesions was found to be essential for bombesin-unduced PC3 cells 
motility (89). Expression of FAK was found to be higher in invasive, highly tumourigenic 
PC3 and DU145 prostate cancer cell lines compared to relatively non-invasive LNCaP 
cells (91). Cell migration required activation of FAK/Src pathways as inhibiting FAK by 
infecting prostate cancer cells with adenovirus carrying focal adhesion kinase-related non-
kinase (FRNK) or treatment by Src inhibitor PP2 significantly reduced migration. In 
LNCaP cells exposed to IL-8, activation of both FAK and Src was necessary to induce cell 
migration whereas Src activity was also required for androgen independent growth (46). 
Proline-rich tyrosine kinase 2 (Pyk2) belongs to FAK family kinases; it is 
structurally and functionally related to FAK.  Pyk2 becomes autophosphorylated at 
tyrosine Y402, analogous to FAK tyrosine Y397 docking site for Src, in response to variety 
of stimuli, including GPCR activation, integrin-ECM engagement and elevation of 
intracellular calcium (92). Although Pyk2 has been linked with various oncogenic 
processes, especially in the regulation of cell migration, its role in prostate cancer remains 
controversial. Sanzione et al. demonstrated that the expression of Pyk2 was highest in 
benign prostatic epithelium and it inversely correlated with prostate cancer grade (93). The 
same group then investigated the role of Pyk2 in proliferation of PC3 prostate cancer cell 
55 
 
line, concluding that Pyk2-promoted cell proliferation and loss of Pyk2 was accompanied 
by acquisition of neuron-like morphology, thus suggesting that the resulting NE-like cells 
then stimulated prostate cancer cell growth in a paracrine fashion (94). In AR-positive 
castratio-resistant prostate cancer cells, ErbB-2 (HER2) activated Pyk2 and, as a result, up-
regulated adhesive properties of prostate cancer cells mainly via activation of MAPK 
thway(95). Although activation of Src was not required to stimulate cell adhesion, Pyk2 
was shown to be autophosphorylated at tyrosine Y402, facilitating interaction with Src and, 
possibly, regulating other cell functions. 
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Figure 14. Regulation of adhesive properties in AR positive castration-resistant 
prostate cancer cells by PYK2. Adapted from Yuan et al. (95). Constitutive activation 
of HER2 is thought to positively regulate adhesive ability of AR-positive prostate 
cancer cells via activation of Pyk2. This process involves MEK and Erk kinases. 
Phosphorylation of Pyk2 at tyrosine Y402 leads to Src activation. Src with p38/MAPK 
regulate multiple downstream targets. 
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Deregulation of Pyk2 in protein complexes facilitating focal adhesion turnover in 
prostate cancer cells has been compared to similar process in osteoclasts where Pyk2 is 
thought to functionally replace FAK (96). Dynamic coordination of focal adhesion 
assembly and disassembly is controlled by Src in association with other proteins, including 
focal adhesion kinases (FAK and Pyk2), members of paxillin family adaptor proteins and 
protein tyrosin phosphatases that dephosphorylate proteins, phosphorylated by tyrosine 
kinases. In PC3 prostate cancer cell line that has been originally derived from bone 
metastases of a patient with metastatic prostatic cancer, Src has been demonstrated to form 
complexes with Pyk2, leupaxin, adaptor protein functionally similar to paxillin, and 
protein tyrosin phosphatase-proline-, glutamate-, serine-, and threonine-rich sequence 
(PTP PEST) (97). Using siRNA approach, the authors showed that inhibition of leupaxin 
in PC3 cells resulted in reduced migration, whereas adenoviral-mediated overexpression of 
leupaxin was associated with activation of Pyk2 and formation of complexes with Src. 
Resulting increase in cell migration was linked with activation of enzyme Rho GTPase, 
regulating Rho family adaptor proteins, including Src substrate Rho GAP (98). 
Ezrin is a member of ERM (ezrin, radixin and moesin) family adaptor proteins 
linking membrane molecules to actin cytoskeleton.  Ezrin has been implicated in various 
oncogenic cellular processes including invasion, migration, survival and its deregulation is 
thought to be an important factor in the development of metastatic disease (99). 
Overexpression of ezrin in prostate cancer has been associated with adverse prognostic 
factors, such as high Gleason score and seminal vesicle invasion (100). Invasive properties 
of prostate cancer cells in response to androgens could be mediated by increased 
expression and phosphorylation of ezrin at threonin and tyrosin residues (101). While 
ROCK and PKCα kinases are responsible for threonin phosphorylation, Src is thought to 
be the main factor in tyrosin phosphorylation of ezrin at several residues, including Y145 
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and Y353. Phosphorylation is preceded by physical association between Src and ezrin, 
binding SH2 domain of Src to putative phosphorylated tyrosine Y190 of ezrin (102). 
Application of Src inhibitor PP2 reduced ezrin phosphorylation and decreased invasive 
capacity of androgen stimulated prostate cancer cells (101). 
Discovery of metastatic suppressor KAI1/CD82 has underlined the importance of 
Src signalling in prostate cancer cell motility. Being a member of transmembrane 4 
superfamily (TM4SF), KAI1/CD82 transmits extracellular stimuli to intracellular 
signalling cascades, thereby regulating variety of cellular processes involved in metastatic 
spread, including adhesion, migration and cytoskeletal rearrangement (103). In prostate 
cancer, down-regulation of KAI1/CD82 expression was found to correlate with high 
Gleason grade and advanced clinical stage (104;105). Several studies have attempted to 
answer the question why the loss of KAI1/CD82 results in increased metastatic potential in 
prostate cancer. In PC3 prostate cancer cell line, expression of KAI1/CD82 resulted in 
reduction of integrin-dependent tans-activation of tyrosine kinase receptor for hepatocyte 
growth factor, scatter factor (HGF/SF) c-Met (106). As previously mentioned, cross-talk 
between integrins and growth factor receptors can initiate downstream activation of 
Src/FAK pathway with subsequent recruitment of various Src substrates, including p130cas. 
Decreased phosphorylation level of Src, FAK at tyrosine Y861, and p130cas upon 
KAI1/CD82 expression led to significant reduction in migration and invasion. Using DU-
145 prostate cancer cell line that is known to express SFK member Lyn rather than Src, 
Zhang et al. reported that reduced activation of Lyn/FAK was not involved in KAI1/CD82 
signalling despite inhibition of p130cas-CrkII complex formation (107). However, overall 
expression levels of Lyn and FAK were found to be increased in KAI1/CD82-positive DU-
145 cells probably due to a compensation mechanism. 
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Figure 15. The role of  KAI1/CD82 in suppressing cell invasion. Adapted from 
Sridhar et al. (106). KAI1/CD82 limits integrin and ligand-induced activation of RTK 
c-Met. There is also independent suppression on Src, activated by integrins. Loss of 
KAI1/CD82 during late stage tumorigenesis results in increased c-Met and Src 
activation together with their downstream targets p130cas and FAK. 
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1.3 SFK and RTK in Prostate Cancer 
 
1.3.1 EGFR 
 
Epidermal growth factor receptor belongs to the family of transmembrane proteins 
with tyrosine kinase activity consisting of four receptors: EGFR (ErbB-1), Her2/neu 
(ErbB-2), Her3 (ErbB-3), Her4 (ErbB-4). Protein expression studies have shown the 
correlation between EGFR expression and progression of prostate cancer to advanced 
disease and hormone independence (108-111), while the role of individual EGFR family 
members remain controversial (112). Although the exact nature of biological synergy 
between EGFR and SFK has not been identified, the cooperation appears to be an 
important factor contributing to aggressive tumour behaviour (113).  
Ligand binding causes EGFR receptors to precipitate into homo- and hetero-dimers 
with other family members, followed by autophosphorylation at several tyrosine residues 
that serve as docking sites for various proteins, including SFK (114). EGFR/SFK complex 
formation leads to conformational rearrangements in Src protein thereby opening the 
catalytic domain for the interaction with downstream targets, among them EGFR itself 
(115). Within activation loop of EGFR catalytic domain, tyrosine Y845 has been identified 
as Src-specific phosphorylation site and it is critical for the receptor function (116). EGFR 
phosphrylated at tyrosine Y845 becomes a relay point, integrating various extracellular 
stimuli, including neuropeptides, cytokines, calcium, UV light, ionizing radiation etc. into 
complex intracellular molecular cascades (117-120).  
Another important mechanism of cooperation between EGFR receptors and SFK is 
the regulation of receptor turnover by phosphorylation of the proteins responsible for 
endocytosis and ubiquitination, including clathrin, dynamnin and E3 ubiquitin ligase Cbl 
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(114). Ligand-bound membrane receptors are clustered to the clathrin-coated pits and 
internalised, which is then followed by dynamin-regulated detachment of endocytic 
vesicles from plasma membrane. Clathrin and dynamin, phosphorylated  by SFK, are 
redistributed to the cell periphery, enhancing endosomal pool of the receptors, stimulating 
continuous receptor signalling from within the vesicles (121). Moreover, SFK-induced 
phosphorylation of Cbl, which is recruited to the activated EGFR in order to promote 
internalisation and degradation, results in Cbl deactivation, further increasing receptor 
availability for recycling (122). 
Signals emanating from EGFR family receptors have been shown to activate AR 
and, as a result, promote proliferation and migration of prostate cancer cells. This is 
achieved by stimulation of androgen-independent AR transcriptional activity (123), 
increase of AR sensitivity to low concentrations of androgens (124), AR complex 
formation with intracellular signalling proteins (44) and direct AR phosphorylation (50).  
SFK have been implicated in modulation of EGF-stimulated AR transcriptional activity 
and EGF-induced prostate cancer cell migration. Increase in AR transcriptional activity 
can be abrogated by selective SFK inhibitor SU6656 (50). The EGF-stimulated growth of 
C-81 prostate cancer cell line in androgen-depleted medium was suppressed by Src siRNA 
and AR siRNA, suggesting that proliferation of prostate cancer cells in androgen-depleted 
conditions is driven by EGF through Src signalling. In LNCaP prostate cancer cell line, 
EGF has been shown to trigger rapid Src/AR/ERβ complex assembly. Src-steroid receptor 
interaction is necessary for EGFR phosphorylation and can be inhibited by androgen 
antagonists (44;45). 
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Figure 16. Cross-talk between EGFR and steroid receptors mediated by Src. Adapted 
from Migliaccio et al. (125). Ligand-bound EGFR phosphorylates ER in complexes 
with AR at tyrosine Y537. This creates a docking site for Src, which becomes activated 
by the release of intramolecular constrains. ER/AR/Src complex formation results in 
EGFR phosphorylation by Src, translating into further downstream signalling. 
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1.3.2 IGFR 
 
There is evidence that IGF family receptors play an important role in prostate 
carcinogenesis (126) and targeting IGF-related axis could potentially be beneficial in the 
management of castration-resistant prostate cancer (127). Two types of IGF receptors 
exist: IGF-1R and IGF-2R that bind two ligands, IGF-1 and IGF-2. IGF-1R represents a 
tetramer with higher affinity for IGF-1; it is made up of two α subunits that bind the ligand 
and two β subunits, possessing tyrosine kinase activity. Of two IGF receptors, IGF-1R is 
considered to be the main oncogenic factor as IGF-2R serves mainly as IGF-2 degradation 
mechanism, lacking tyrosine kinase domain. In vitro studies have demonstrated that IGF-
1R downstream signalling via MAPK pathway may promote proliferation of prostate 
cancer cells whereas involvement of PI3K-Akt pathway is required to inhibit apoptosis 
(126). 
Ligand-bound IGF-1R activates insulin receptor substrate protein (IRS), which 
displays multiple binding sites for SH2 homology domain-containing proteins, including 
SFK (12). Experiments using 3T3-L1 murine preadipocytes have shown that Src and Fyn 
mediate IGF-induced phosphorylation of adaptor protein Shc and MAPK activation (128). 
Introduction of dominant-negative Src abolished Shc and MAPK activation but not IRS, 
suggesting that SFK act upstream in relation to MAPK pathway. Evidence of SFK 
involvement in IGF-activated PI3K-Akt cascade has come from the studies of phosphatase 
and tensin homolog deleted on chromosome ten (PTEN) tumour suppressor that inhibits 
activation of Akt by IGF-1R. Stable overexpression of PTEN in PC-3 prostate cancer cells 
resulted in reduced IGF-1R synthesis, inhibition of proliferation and increased apoptosis 
(129). Rather than supressing PTEN enzymatic function, SFK seem to interfere with the 
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ability of PTEN to bind to the cellular membrane where its main activities take place 
(130). 
Interaction between IGF system and steroid receptor signalling is thought to play an 
important role in prostatic carcinogenesis, although the precise mechanism of action is not 
completely understood (131;132). Androgens have been shown to up-regulate IGF-1R 
expression and IGF-1-induced Src/MAPK signalling in AR-positive prostate cancer cells 
(133). Interestingly, although AR requirement for this process was demonstrated by the 
lack of IGF-1R overexpression in AR-negative PC-3 cells, it did not depend on AR 
transcriptional activity. Furthermore, androgen-stimulated IGF-1R up-regulation was 
suppressed by both Src inhibitor PP2 and MEK-1 inhibitor PD98059. Activation of 
oestrogen receptor β (ERβ), known to form complexes with Src and AR in prostate cancer 
cells, can result in similar effect on IGF-1R expression and activation (134). Activation of 
ERβ by oestrogens increased IGF-1R sensitivity to IGF-1 and, as a result, stimulated 
downstream signalling via Src/MAPK and, to a lesser degree, PI3K-Akt cascades. The 
relationship between steroid hormones and IGF-1R appears to be mutual as IGF-1 has 
been shown to increase AR sensitivity to low concentration of androgens (135).  
Castration-resistant prostate cancer cells are thought to rely on growth factors for 
their proliferative needs in androgen-depleted conditions and IGF signalling has been 
implicated in the development of CRPC (126).  Krueckl et al. studied biological effects of 
IGF in LNCaP prostate cancer cells that are androgen sensitive and in the cell line C4-2, 
which was derived from parental LNCaP cells, capable of growing in androgen-depleted 
media (136).  The authors concluded that under androgen-deprived conditions, the 
response to IGF stimulation was proportional to IGF-1R expression and that in LNCaP cell 
this effect was dependent on androgens, whereas C4-2 cells exhibited androgen-
independent IGF-1R expression, activation and Akt signalling (137). IGF-1R can be trans-
activated by nueropeptides, representing another potential mechanism of castration 
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resistance in prostate cancer. In TSU-Pr1 prostate cancer cell line, this process was 
mediated by Src and PI3K  and inhibited by the expression of NEP (138). 
 
1.3.3 VEGFR 
 
Several growth factors, among them VEGF, promote angiogenesis, an important 
process required for the growth and spread of prostate cancer. VEGF system consists of 
VEGF family pro-angiogenic proteins (five main isoforms: A, B, C, D and E) and three 
types of trans-membrane receptors: VEGFR-1, VEGFR-2 and VEGFR-3. Biological 
responses resulting from VEGF signalling are mediated mainly through VEGFR-2 due to 
its high tyrosine kinase activity (139). VEGF family proteins and receptors have 
significant diagnostic, prognostic and therapeutic potential in prostate cancer and targeting 
VEGF with neutralising antibodies has been shown to reduce tumour progression in 
patients with prostate cancer and prevent formation of metastatic deposits (140).  
The role SFK play in VEGF system is similar to the mutual relationship with other 
tyrosine kinase receptors. Downstream signals transmitted from ligand-bound VEGFR-2 
can activate SFK, which in turn can lead to the increase in VEGF expression. Activated 
EGFR-2 undergoes autophosphorylation at several tyrosin residues, including Y951 and 
Y1212, creating consensus sequences for binding SH2 domain of Src (141;142).  Gambogic 
acid, which is the main active substance in traditional Chinese medicine Gamboge 
hanburyi, has been shown to inhibit VEGFR-2 activation and downstream signalling in 
vitro and in vivo (143). Using human umbilical vein endothelial cells (HUVEC) and PC3 
prostate cancer cell line, Yi et al. demonstrated that gambogic acid significantly inhibited 
angiogenesis, as indicated by new microvessel growth and tumour cell proliferation in PC3 
xenografts in SCID mice. Furthermore, inhibition of VEGFR-2 phosphorylation by 
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gambogic acid was associated with reduced activation of Src and FAK, which correlated 
with inhibited proliferation and migration.  
Although activated SFK do not seem to phosphorylate VEGFR-2 following physical 
association, unlike EGFR or IGFR, SFK are thought to up-regulate VEGF system by 
increasing VEGF protein expression. SFK-dependent pathways can be activated in 
response to various extracellular stimuli, including hypoxia or radiation that have been 
shown to compromise the effect of chemotherapy and radiotherapy in prostate cancer 
(144). Src, activated by hypoxia or radiation, has been demonstrated to phosphorylate 
signal transducer and activator of transcription proteins 3 (STAT3). Activated cytoplasmic 
STAT3 formed homodimers or heterodimers with STAT1 and translocated to the nucleus, 
binding to the target genes, thereby promoting transcription of various proteins, among 
them hypoxia inducible factor 1 alpha (HIF-1α). Up-regulation and stabilisation of HIF-1α 
by activated Src led to HIF-1α nuclear translocation, dimerisation with HIF-1β and 
physical association with transcription coactivators CREB binding protein/p300 
(CDP/p300) and apurinic/apyrimidinic endonuclease 1/Redox effector factor 1 (APE1/Ref-
1). Together these proteins formed transcription complex, binding to VEGF promoter and, 
thus, increasing VEGF expression (145). 
SFK-induced VEGF expression in prostate cancer cells can be inhibited by soy 
isoflavones (146), adenoviral vector expressing the melanoma differentiation-associated 
gene-7 (Ad-mda7) (147) or overexpression of Src-suppressed C-kinase substrate 
(SSeCKS) (148). Soy isoflavones, the dietary components of soy-rich food, possibly 
contributing to the lower rate of prostate cancer in Asian population, have been shown to 
inhibit several protein tyrosine kinases, including Src (149). Pre-treatment with genistein, 
the most biologically active substance of isoflavones, can increase radiosensitivity of 
prostate cancer cells to radiotherapy, inhibiting molecular cascades stimulated by ionising 
radiation. Down-regulation of Src/STAT3/HIF-1α pathway by soy isoflavones in PC3 and 
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C4-2 castration-resistant prostate cancer cell lines, inhibited survival mechanisms and 
VEGF expression, which correlated with reduced expression of APE1/Ref-1and decreased 
DNA binding capacity of HIF-1α and NF-κB (146). In another experiment, treatment of 
LNCaP and DU-145 prostate cancer cells with Ad-mda7 inhibited Src kinase activity, 
which prevented STAT3 binding to VEGF promoter and resulted in reduced VEGF 
mRNA and protein level (147). Finally, tetracycline-stimulated re-expression of SSeCKS 
in MatLyLu prostate cancer cells prevented formation of lung metastases in nude mice by 
inhibiting VEGF expression and associated microvessel formation at metastatic sites, 
although the primary tumour growth was not significantly affected (148). 
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1.4 SFK Inhibitors 
 
1.4.1 Development Strategies and Preclinical Studies 
 
Recent advances in the research investigating the involvement of SFK in multiple 
signalling networks have led to the increased interest in the development of SFK inhibitors 
that can be used in the treatment of prostate cancer and other malignancies (150). Since 
SFK activation rather than total protein overexpression is considered to be the main driver 
of oncogenic processes, the development strategies have been focused on targeting specific 
activation mechanisms. The success so far has been achieved with the development of 
chemical compounds inhibiting catalytic activity of Src based on ATP competitive binding 
to the tyrosine kinase domain, inhibiting its enzymatic activity. The binding model was 
created according to X-ray crystallographic analysis of SFK members Src and Hck by 
determining spatial orientation of inhibitor molecule bound to the kinase domain (151).  
Progress in information technologies has now been used to increase the efficiency and 
accuracy of testing the chemicals that potentially could be used to inhibit SFK and other 
tyrosine kinases, based on complementing the traditional high-throughput screening with 
virtual analysis of computer-generated spatial images (152).  
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Figure 17. Binding mode of Src inhibitor CGP77675 to the ATP binding pocket of 
Hck tyrosine kinase domain. Adapted from Suza et al. (151). The inhibitor is 
presented in ball-and-stick mode, whereas the aminoacids surrounding the ATP 
binding pocket are shown in surface mode. The amino acids, contributing to 
hydrogen bond interaction are shown in yellow. CGP77675 exhibits the 
characteristics of a typical tyrosine kinase inhibitor. 
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At the time of writing, several catalytic Src inhibitors have progressed beyond the 
laboratory experiments and are currently undergoing the testing in clinical trials, among 
them dasatinib (BMS354825, Bristol Myers Squibb), bosutinib (SKI606, Wyeth) and 
AZD0530 (Astra-Zeneca). Dasatinib has emerged as a frontrunner; recently it has been 
given the US Food and Drug Administration Agency (FDA) approval for the treatment of 
adults with chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive 
acute lymphoblastic leukaemia (Ph+ALL) with resistance to prior therapy. Dasatinib has 
shown effectiveness in vitro and in vivo using various cancer models, including lung 
cancer (153), cancer of pancreas (154), head and neck cancer (155) and human sarcoma 
(156).  
In vitro experiments have demonstrated that dasatinib affected proliferation, 
adhesion, migration and invasion of various prostate cancer cell lines. Lombardo et al. 
reported inhibition of proliferation of PC3 cells by dasatinib with inhibitor concentration 
(IC50) 9.4 nM, based on tetrazolium dye conversion test (157). Using LNCaP and DU-145 
cell lines, Nam et al. showed that dasatinib inhibited adhesion, migration and invasion; this 
was associated with suppressed activity of SFK Src and Lyn (158). Interestingly, although 
downstream SFK/FAK/p130cas signalling pathway was also suppressed, the decrease in 
phosphorylation of STAT3, MAPK or Akt could not be demonstrated. PC3-derived cell 
lines PC-3MM2GL, which are AR-negative, and PC-3AR-A1cells, transfected with vector 
carrying functional AR, have been used to test the efficacy of dasatinib in vivo (18). 
Dasatinib treatment of mice implanted with androgen-sensitive PC-3AR-A1 as well as 
castration-resistant PC-3MM2GL cells resulted in significant suppression of both primary 
tumour growth and lymph node metastases. 
AZD0530 is a highly selective orally available dual SFK/Abl inhibitor in clinical 
development for treatment of many solid tumours, including prostate cancer (159). 
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AZD0530 has shown anti-proliferative activity in vitro against PC3 prostate cancer cell 
line with IC50 of 0.7 µM (160). Chang et al. has recently published a comprehensive study 
of molecular pathways involved in Src signalling in prostate cancer and immortalised 
normal prostate epithelial cell lines (161). The authors demonstrated that proliferation of 
DU-145 and PC3 prostate cancer cell lines was inhibited by AZD0530 due to down-
regulation of cyclin D1, β-catenin, c-Myc and induction of G1/S cell cycle arrest. 
Interestingly, while in DU-145 cells cyclin D1 and c-Myc were regulated by Src/MAPK, 
PC3 cells utilised Src/Ras/Akt/GSK3β molecular pathway, although both cell lines did not 
display STAT3 involvement. As previously mentioned, cell migration was significantly 
inhibited by AZD0530 via Src/FAK/p130cas signalling. Administration of AZD0530 to 
SCID mice orthotopically implanted with DU-145 xenografts suppressed the tumour 
growth by 45% compared to controls. Finally, effectiveness of AZD0530 was 
demonstrated in neuropeptides-autocrine model of hormone-resistant prostate cancer, 
where the inhibitor suppressed Src-mediated AR transactivation by GRP  (74).  
Several other catalytic Src inhibitory compounds have shown effectiveness against 
prostate cancer in laboratory experiments. CGP76030 and CGP77675 (Novartis) 
pyrrolopyrimidine chemicals reduced proliferation, adhesion, migration and invasion of 
PC3 cell line, which was time- and concentration-dependent (16). This was the result of 
Src inhibition and down-regulation of the expression of MMP-9 and the tissue inhibitor of 
metalloproteinases 1 (TIMP-1). Pyrazolo[3,4-d]pyrimidines SI35 and SI40 were employed 
to study the role of Src activation in mediating EGF-induced migration using PC3 cell line 
model (162). These substances, structurally related to pyrazolo-pyrimidine-based PP1 and 
PP2 SFK inhibitors that have been extensively used in vitro (43;46;91), have proved 
effective in reducing growth factor-induced cell migration at concentrations corresponding 
to the inhibition of SFK activity. Although anti-proliferative activity was also shown, 
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much higher concentrations of Src inhibitors were required, suggesting possible non-
specific mechanism of action. 
Physical association between Src and its substrates provides an attractive targeting 
mechanism in the development of inhibitory compounds. Detailed structural analysis of 
Src docking sites has made it possible to produce short peptides that could be used to 
prevent the binding of substrates. Sequence-based peptide inhibitor KRX-123 has been 
designed to prevent the interaction between the substrates and HJ loop in the Lyn kinase 
domain, which in theory should improve the specificity of the inhibitor (15). In vitro and in 
vivo experiments using PC3 and DU-145 cell lines, conducted to establish the 
effectiveness of KRX-123 in prostate cancer, revealed inhibition of proliferation, induction 
of apoptosis and regression of tumour explants in nude mice. The inhibitor was shown to 
be Lyn-specific, inhibiting Lyn trans-phosphorylation in a dose-dependent manner with 
IC50 of app.1µM, while phosphorylation of related SFK Lck and Fyn was not affected. 
Similar approach has been used to construct a short interfering peptide, mimicking AR 
proline-rich sequences, interacting with SH3 domain of Src (163). This 10 amino-acid long 
synthetic substance prevented AR/ER/Src complex assembly, affecting G1 to S cell cycle 
progression, cyclin D1 expression and DNA synthesis in AR-positive prostate cancer cells. 
The findings were further confirmed by in vivo experiments, where the inhibitor 
suppressed the growth of LNCaP xenografts in nude mice. 
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Figure 18. Short peptides inhibit AR/ER/Src interaction. Adapted from Migliaccio et 
al. (164). In human prostate cancer cell androgens induce complex formation 
between ER/AR and Src. Src then becomes activated by the release of intramolecular 
constrains, followed by activation of downstream targets. ER/AR/Srs complexes 
could be disrupted by shirt peptides that mimic AR and ER docking sites on Src. 
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1.4.2 Biomarkers of Sensitivity to SFK Inhibitors 
 
Recent progress in the development of small molecule inhibitors has highlighted the 
importance of tailoring the treatment to the individual tumour profile due to significant 
heterogeneity of malignancies and difficulty predicting the therapeutic response. 
Biomarkers represent an important diagnostic and prognostic tool, used to test the 
likelihood of each particular individual with cancer responding to the inhibition of certain 
molecular pathway as well as monitor and correct the concentration of drugs to produce 
the desired biological effect. Gene microarray analysis has been used to identify in vitro 
and in vivo genomic signatures representing the genes up-regulated in the tumour cells 
responding to each particular therapeutic agent (165). 
 Identification and validation of AR genetic signature in prostate cancer patients, 
undergoing hormone deprivation therapy may allow more accurate estimation of 
individual hormonal status and intraprostatic DHT level (166). As expected, the 
application of AR signature revealed higher AR activity in untreated, hormone naïve 
tumours and lower AR activity in tumour samples, taken from the individuals undergoing 
hormone deprivation therapy and the patients with CRPC. More importantly, there was a 
significant correlation between reduced AR activity in CRPC samples and increased Src 
pathway activity, as defined by Src genetic signature (167), which was further supported 
by the increased predicted sensitivity to SFK inhibitor dasatinib.  
Determining gene expression profiles in order to create genomic signatures has 
increasingly been used to separate patients’ subsets according to the prognosis and the 
potential for targeting activated molecular pathways. Using large collection of human 
cancers, Bild et al. studied the patterns of gene expression and their clinical relevance with 
regards to disease outcomes (167).  Several pathway deregulation signatures ware 
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identified, including Src, Ras and Myc signatures that were further confirmed by using 
specific SFK inhibitor SU6656. This Src signature was then applied to test the sensitivity 
of prostatic cell lines PC3 and MDAPCa-2b to the treatment with dasatinib in vitro and in 
vivo (168). While the proliferation of PC3 cells was suppressed by dasatinib, the treatment 
of MDAPCa-2b cells did not result in significant inhibition of proliferation. Genetic Src 
signature was then tested in vivo for the xenografts of these cell lines and was found to 
match perfectly with predicted anti-tumour activity. 
As it is not always possible to obtain tumour tissue samples in clinical settings, the 
search for biomarkers has been concentrated on identifying the substances contained in the 
tumour and in the blood that would respond to the treatment in similar fashion.  SFK 
inhibitors have the advantage in this respect as the peripheral blood mononuclear cells 
(PBMCs) contain abundant quantities of SFK and, therefore, provide sufficient read-outs 
of SFK activity (169). Activated form of Src pSrcY419 has been proposed as a reliable 
biomarker of Src inhibition, allowing rigorous assessment of pharmacokinetic and 
pharmacodynamic properties of the drugs and their relationship with anti-tumour activity. 
Evaluation of pSrcY419 inhibition by dasatinib in mice bearing PC3 xenografts revealed 
that similar inhibitor concentration and time were required to suppress Src activity in the 
tumour and in PBMCs. The effect of dasatinib on tumour growth was dependent on 
inhibition of Src activity, which was found to be similarly suppressed  by dasatinib in 
tumour samples and in PBMCs (170). 
 
1.4.3 SFK Inhibitors in Metastatic Bone Disease 
 
Significant morbidity and mortality associated with bone metastases in advanced 
prostate cancer represent a serious clinical problem (171). Severe pain, pathological 
fractures, hypercalcaemia and spinal cord compression are the complications of metastatic 
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bone disease in prostate cancer, frequently limiting the lifespan of the patients. Propensity 
of prostate cancer cells to metastasise to the bones is well known and the relationship 
between tumour cells and bone microenvironment plays a pivotal role in this process 
(172). Although the introduction of chemotherapy, radiotherapy and bisphosphonates has 
improved the outcomes, it is the progress in our understanding of intricate molecular 
mechanisms, governing the processes involved in metastatic spread of tumours, provides 
the grounds for hope of cure and prevention (173). 
The role of SFK signalling in normal bone physiology and metastatic bone disease 
was originally highlighted by the experiments with Src knockout mice that were 
surprisingly healthy apart from osteopetrosis and the lack of erupted teeth, due to deficient 
osteoclast function (174). The mice had high number of osteoclasts undergoing normal 
osteoclastogenesis, although mature cells failed to form ruffled membrane border 
necessary for bone resorption (175). At molecular level, SFK, activated by integrins in 
complexes with Pyk-2, phosphorylates various substrates, including Cbl and becomes 
involved in multiple cascades with receptor activator of nuclear factor κB (RANK) (176). 
Positive regulation of osteoclasts by SFK is complemented by reduced osteoblasts 
differentiation and increase in bone turnover (177). 
In normal bone tissue, bone resorption by osteoclasts and new bone formation by 
osteoblasts exist in equilibrium, which is disrupted by tumour invasion. Resulting lesions 
could be osteoblastic or osteolytic in nature, depending on predominant activation of 
osteoblasts in former or osteoblasts in latter . Although bone metastases in prostate cancer 
are mostly osteoblastic, the initial stages of metastasis formation are accompanied by the 
increase in osteolytic activity (178). In addition, osteolytic processes occur in the 
background of skeletal metastases in prostate cancer. Once the tumour deposits become 
established in the bones, cancer cells release growth factors into the bone 
microenvironment, including transforming growth factor β (TGFβ), fibroblast growth 
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factor (FGF), IGF, PDGF etc. Growth factors stimulate Src-mediated osteoclast activity, 
leading to further bone destruction and release of biologically active substances from the 
bone matrix, stimulating the proliferation and migration of tumour cells (179). This 
positive feedback mechanism, frequently described as a ‘vicious circle’ of bone 
metastases, can be targeted by Src inhibitors due to the role Src plays in cancer, 
angiogenesis and bone metabolism (180). 
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Figure 19. ‘Vicious circle’ of bone metastases. Adapted from Rucci et al. (181). 
Tumour cells, established in bone marrow, produce various substances (IL-6, TNFα, 
M-CSF, PGE-2, PTHrP) which stimulated osteoclastogenesis (OC) directly or by 
increasing RANKL expression in osteoblasts (OB). Increase in osteoclasts formation 
leads to bone resorption followed by the release of growth factors from the bone 
matrix (BMPs, PDGF, IGF-I, FGF etc.) that stimulate tumour growth. 
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Small molecule SFK inhibitors with anti-tumour activity have been studied to define 
whether they could be used for the treatment or prevention of metastatic bone disease. In 
pre-clinical experiments, dasatinib inhibited proliferation of osteoclasts in bone marrow 
cell culture and reduced bone resoption in animal model using thyro-parathyroidectomised 
(TPTX) male Sprague-Dawley rats (182). Using mouse fetal calvarial explants and 
isolated rabbit osteoclasts, de Vries et al. demonstrated that Src inhibitor AZD0530 
suppressed osteoclasts activity and osteoclastogenesis, implying that SFK activity is 
essential for the initial phase of osteoclasts formation. Furthermore, the inhibitor prevented 
osteoclasts migration to the bone surface and disrupted formation of actin rings and 
resorption pits (183). CGP77675, pyrrolopyrimidine analogue that was used to inhibit 
proliferation and migration of bone metastasis-derived PC3 cell line (16), was shown to 
inhibit bone resorption in rat foetal long bone cultures and prevented bone loss in young 
ovariectomised rats (184). Purine-based compounds AP22161, AP22408 and AP23541 
(ARIAD) represent a series of Src inhibitors, targeting SH2 domain and, thus, preventing 
protein-protein interaction. These chemicals incorporate a bisphosphonate group that 
confer bone-specific properties, achieving relative tissue selectivity (185-187). 
 
1.4.4 SFK Inhibitors in Prostate Cancer Clinical Trials 
 
Phase I and phase II clinical trials are now under way exploring potential efficacy of 
Src inhibitors dasatinib and AZD0530 in patients with castration-resistant prostate cancer. 
As a result of the FDA approval of dasatinib for the use in imatinib-resistant chronic 
myeloid leukaemia, the side effect and toxicity are best described for dasatinib. 
Reassuringly, the toxicity has been relatively mild, with pleural effusion accounted for the 
majority of patients who had to come off the phase I study in solid tumours (188).  
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Preliminary results for dasatinib and final results for AZD0530 as single agents in phase II 
trials in patients with castration-resistant prostate cancer have now been published. While 
the final results from phase II study of AZD0530 as a monotherapy did not show any 
clinical efficacy, the preliminary results from phase II study using dasatinib are more 
encouraging. 
AZD0530 was tested in phase I clinical trials and was proven to well tolerated by 
healthy volunteers in doses up to 1000 mg. Further single dose escalation resulted in 
diarrhoea and vomiting, while the subjects taking lower doses over longer period 
experienced rash, flu-like symptoms, myalgia, arthralgia, headache, mild diarrhoea and 
raised creatinin (189). Another phase I study of AZD0530 in patients with cancer revealed 
acceptable tolerability with minimal side effect and positive response using FAK and 
paxillin phosphorylation as biomarkers. Paired tumour biopsies were obtained, before and 
after treatment that were stained by immunohistochemical method with antibodies against 
phosphorylated FAK and paxillin. Blind assessment of biopsy staining by pathology panel 
confirmed the modulation of phosphorylation and cellular localisation of selected 
biomarkers, consistent with AZD0530 therapy (190).  
Despite promising pre-clinical data and the results of phase I studies, AZD0530 did 
not seem to be clinically effective in phase II clinical trial as a monotherapy in patients 
with hormone-resistant prostate cancer. 28 patients were recruited altogether, with 9 
patients previously had taxane-based therapy and failed. PSA reduction greater than 30% 
was chosen as a primary end-point and the dose of 175mg of AZD0530 once daily was the 
treatment regimen. Although the majority of patients tolerated the treatment well, 5 cases 
of grade 3 toxicities were recorded, including liver toxicity, nausea, vomiting, 
lymphopenia and 1 patient unexpectedly died from various co-morbidities. Only 5 patients 
had transient PSA reduction with none achieving PSA response criteria. Based on strong 
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pre-clinical evidence, the authors concluded that further studies are warranted, perhaps as a 
combination therapy, or earlier stages of prostate cancer should be targeted (191). 
Preliminary results from phase II trial of dasatinib as monotherapy in metastatic 
castratio-resistant prostate cancer are now available (192). The patients’ cohort included 
46 subjects with biochemical evidence of hormone relapse showing castrate levels of 
testosterone with no prior chemotherapy. Disease progress was measured using response 
evaluation criteria in solid tumours (RECIST) taking into account the composite of PSA 
levels and bone scan appearances. Urinary N-telopeptide estimation as a measure of bone 
metabolism, was determined on a 4 weekly basis. The disease stabilised with the treatment 
in 10(67%) patients out of 15, who could be evaluated using RECIST criteria. 27 patients 
had bone scan at 12 weeks, in 16(59%) patients metastatic disease was stable and in 1 
patient it improved. PSA doubling time was better in 29(80%) patients out 36 evaluated 
and in 1 patient who had more than 2 PSA measurements, PSA declined from 19.3 to 3.3 
ng/ml. Bone metabolism slowed in 21(57%) out of 37 evaluable patients as demonstrated 
by the decrease in urinary N-telopeptide by more than 35%. Several clinical trials are now 
under way to investigate the efficacy of dasatinib in CRPC in combination with 
prednisolone, docetaxel, VEGFR monoclonal antibody bavacizumab and as neo-adjuvant 
therapy with LHRH analogue therapy prior to radical prostatectomy (193). 
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1.5 Hypothesis and Statement of Aims  
 
Src family kinases have been shown to play an important role in the development of 
prostate cancer and progression of prostate cancer to castration resistance. Multiple in vitro 
experiments have shown that SFK activation is necessary for the prostate cancer cells to 
migrate and invade. However, it has not been known whether the increase in SFK 
expression or activity in patients with prostate cancer has any effect on tumour growth or 
clinical parameters, including survival. As SFK inhibitors are now in Phase II clinical trials 
for the treatment of castration-resistant prostate cancer, translational studies of SFK in 
prostate cancer patients are urgently required. 
We therefore hypothesised that SFK activation in the transition of prostate cancer 
from hormone-sensitive disease to castration-resistant state is associated with negative 
prognosis and stimulates the development of bone metastases. 
 
Project aims: 
1. To expand pre-existing database of paired prostate tumour samples, taken from 
the prostate cancer patients prior to androgen-deprivation therapy and following 
the development of castration resistance.  
2. To select and optimise antibodies for the detection of SFK expression and 
activation in human prostate tumour samples, using paraffin-embedded sections. 
3. To correlate SFK immunostaining with clinical parameters, including survival 
and the presence of bone metastases. 
4. To characterise hormone-sensitive LNCaP and its counterpart LNCaP-SDM 
castration-resistant cell lines. 
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5. To investigate the effect of androgen deprivation on SFK activity in  LNCaP and 
LNCaP-SDM cell lines. 
6. To examine the application of SFK inhibitor dasatinib in proliferation and 
migration studies using prostate cancer cell lines. 
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MATERIALS AND METHODS 
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2.1 Development of Clinical Database 
 
Ethical approval was obtained for the retrospective recruitment of patients from 
Multiple Research Ethics Committee for Scotland (MREC) and, subsequently, applications 
were submitted to the Local Research Ethics Committees (LREC) for the site-specific 
assessment. Permission was granted to recruit by LREC NHS Greater Glasgow (Gartnavel 
General Hospital, Southern General Hospital, Western Infirmary and Royal Alexandra 
Hospital) and NHS Lanarkshire (Monklands Hospital, Hairmyres Hospital and Wishaw 
General Hospital). Patients’ details were initially obtained from the local pathology 
departments at each site by performing pathology database searches, selecting prostate 
cancer patients undergoing palliative ‘channel’ trans-urethral resection of prostate (TURP). 
Medical records of selected patients were obtained and detailed analysis was performed 
according to the strict selection criteria to identify those who could be added to the existing 
database.  
Each patient in the cohort was required to have prostate tissue samples taken prior to 
hormone deprivation therapy by means of TURP or trans-rectal ultrasound scan-guided 
(TRUS) biopsy of prostate and more than 50% fall in PSA as an indicator of response to 
androgen deprivation therapy. TRUS biopsies consisted of minimum 12 cores from both 
left and right prostatic lobes with minimum 4 cores taken from the transition zone. 
Subsequent, second line hormonal therapy was then administered to which the patient did 
not respond and PSA concentrations continued to rise above the PSA nadir to 
concentrations greater than 0.2ng/ml. The second prostate tissue sample was taken during 
‘channel’ TURP, performed to relieve the symptoms of bladder outflow obstruction, after 
failure to respond to the second line hormonal therapy and following at least 2 sequential 
rises in PSA level above 0.2ng/ml, indicating biochemical relapse. 
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Clinical information, recorded from the case sheets, included the dates of diagnosis, 
biochemical relapse, death or last follow-up. Type of androgen deprivation therapy was 
noted, whether it was LHRH agonists or surgical orchidectomy. Depending on the results 
of the bone scan, the patients were considered to have locally advanced or metastatic 
disease and the results of repeat bone scan were considered for the patients who developed 
bone metastases whilst on treatment. Pathological data consisted of pathology database 
numbers, required to retrieve the tissue blocks, Gleason grade of hormone naive and 
hormone refractory tumours and the type of procedure used to harvest the tissue (TRUS 
biopsy or TURP).  Information was also recorded on patients receiving radiotherapy with 
the intent of cure or for palliative purposes as well as secondary anti-androgen therapy was 
noted. The majority of patients died by the time the data was analysed, the details of death, 
including the date and causes of death were recorded from clinical case notes if available 
or by contacting the Registry Office. The patients who were alive at the time of analysis of 
data, the date of last follow-up (censored data) were used to calculate survival. 
 
2.2 Immunohistochemistry 
 
2.2.1 Preparation of Tissue Sections 
 
Following the retrieval of formalin-fixed paraffin-embedded tissue blocks from 
pathology archives, each set was assigned a number for coding purposes and identification 
of patients was removed in order to make tissue slides anonymous. It was deemed 
necessary for this project to use full sections and not tissue microarrays due to the 
heterogeneous nature of prostate cancer. Prior to cutting tissue sections, the blocks were 
cooled on the tissue cooler to -100C. Using Leica RM 1235 microtome, 5 µm tissue 
sections were cut and applied onto silane-coated glass slides. The treatment of glass slides 
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with aminopropyltriethoxysilane was necessary to produce greater adherence of the tissue 
section to the glass. Silane coating was done by immersing the glass slides in acetone for 5 
minutes, followed by exposure to 2% silane for 5 minutes. The excess of silane was 
removed by washing the slides in running water and after keeping the glass slides in tap 
water for 20 minutes, the slides were allowed to dry in the fume hood overnight. 
 
2.2.2 Immunohistochemistry Principles and Protocol 
 
Immunohistochemistry (IHC) is a tissue staining technique based on the binding of 
specific antibodies to antigens and detection of this binding in order to localise proteins in 
cells. IHC is widely employed in clinical practice and in basic science research to identify 
and localise differentially expressed proteins in biological tissues. Visualising of antigen-
antibody reaction is accomplished by several methods, the most common being indirect 
immunoperoxidase technique. Initially, the antigen must be exposed to the primary 
antibody, which can be done by immersing tissue sections in citrate buffer under increased 
pressure conditions. Primary antibodies, which could be monoclonal or polyclonal, 
depending on whether they are raised from the single or several clones of plasma cells, are 
subsequently applied. The next stage involves reaction of primary antibody with 
biotinylated secondary antibody, labelled with enzyme horseraddish peroxidase (HRP). 
Finally, visualisation is accomplished upon addition of 3,3’-Diaminobenzidine (DAB), 
which reacts with HRP to produce an insoluble, brown coloured product. 
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Prostate tissue sections were dewaxed in xylene and rehydrated in graded alcohol. 
Antigen retrieval was performed under pressure for 5 min in citrate buffer (pH adjusted to 
6.0). Endogenous peroxidase was inactivated in 0.3% hydrogen peroxide for 10 min and 
the slides were blocked using 1.5% horse serum. Incubation with primary antibody was 
performed in humidified chamber overnight at 40C (anti-phospho SrcY419 1:250 and anti-
phospho SrcY530 1:100, Cell Signalling Technologies, FGR 1:100, Abgent and Lyn 1:10, 
BD Biosciences) or for 1 hour at room temperature for total Src (1:1000, Cell Signalling 
Technologies). Tissue was then incubated in Envision solution (DAKO, UK) for 30 min 
and developed by application of 3,3’-diaminobenzidine (DAB) as a chromogen (DAKO, 
UK). Sections were counterstained with haematoxylin, dehydrated through graded alcohol 
and xylene and mounted in DPX.  In each immunohistochemistry run LNCaP cell pellets 
and colon tissue is included as positive controls and an isotype matched antibody is used 
on colon and prostate samples to provide a negative control. 
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2.2.3 Histoscoring method 
 
All immunostained tumour sections were quantified blindly by two independent 
observers, using a weighted histoscore method at high magnification (x400). Membrane 
and cytoplasm staining were scored separately. Specific staining in each tissue section was 
allocated 0 (no staining), 1 (weak intensity of staining), 2 (moderate intensity), or 3 (strong 
intensity). The final score (maximum 300) is calculated from the sum of: 
 
 
 
 
 
2.3 Cell Culture 
 
Prostate cancer cell lines LNCaP and LNCaP-SDM were a kind gift from Professor 
C Robson (Northern Institute for Cancer Research, Newcastle). LNCaP cells were 
routinely maintained in RPMI 1640 (Invitrogen, UK) containing phenol red and 
supplemented with 10% foetal calf serum (Invitrogen, UK), and 1% glutamine. LNCaP-
SDM cells have been developed using parental LNCaP cells as a model of hormone 
resistant prostate cancer by gradual withdrawal of androgens from the medium. These cells 
were routinely cultured in RPMI 1640 supplemented with 1% glutamine and 10% 
charcoal-stripped foetal calf serum (Cambrex, UK) known to contain negligible amount of 
androgens (194).  
Liquid nitrogen was used to cryopreserve the cells that were grown, split and frozen 
in order to use early passages for each experiment. To facilitate the detachment of the 
cells, routinely kept in 250 ml plastic flasks, after washing with PBS the cells were 
exposed to trypsin and then suspended in culture medium. Approximately 1x106 cells were 
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placed in the centrifuge and pelleted at 1500 rpm for 10 minutes. The cell pellets re-
suspended in freezing medium (10% dimethylsulfoxide, 20% foetal calf serum and 70% 
culture medium), placed in the freezer at -200C, and, after several hours, transferred into 
the liquid nitrogen, where the cells were kept until required. To raise the cell from frozen, 
the cryotubes containing the cells were retrieved from the liquid nitrogen and rapidly 
defrosted in water bath for 30 sec at +370C. Defrosted cell pellet was then transferred in to 
the flask, containing appropriate culture medium and placed in the incubator. 
 
2.4 Cell Count 
 
2.4.1 Cell Count Method 
 
Trypan blue exclusion method was used to count the cells exposed to DHT. 25 µl of 
cell suspension was mixed with the same amount of trypan blue (Sigma, UK) and the 
mixture was loaded into Neubauer haemocytometer. The cells were counted under light 
microscope (magnification x100) excluding non-viable cells stained blue. Total number of 
cells was calculated according to the following equation: 
 
 
 
 
 
91 
 
 
 
Figure 1. Cell count using Neubauer haemocytometer. The cells counted in each of 
the 4 corne squares and the total number of the cells calculated using the equation 
above.
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2.4.2 DHT Stimulation 
 
LNCaP and LNCaP-SDM cells were seeded in 24 well plates at concentration 5x104 
cells per well. 48 hours prior to seeding, full foetal calf serum was changed for LNCaP 
cells to charcoal-stripped foetal calf serum in order to eliminate endogenous steroids. 
LNCaP-SDM cells were kept in the medium containing charcoal-stripped foetal calf serum 
routinely. The cells were allowed to attach overnight and the following day each 4 wells 
were treated with the range of DHT concentrations (0.1 nM, 1 nM, 10 nM, 100 nM). 
Control wells for both cell lines contained the medium with either charcoal-stripped foetal 
calf serum or full foetal calf serum. The following 3 days, the cells were counted using 
trypan blue exclusion method and the final result was the average of 4 wells. The 
experiment was repeated 3 times. 
 
2.5 Western Blot 
 
2.5.1 Determination of Protein Concentration 
 
Cells were grown in standard Petri dishes to the required density. The dishes were 
place on ice, the medium removed and the cells were washed in ice-cold PBS twice. Lysis 
buffer was then applied and the cells were removed using cell scrapers. The tubes 
containing cell lysates were kept in ice for further 30 minutes prior to spinning at 12000 
rpm for 10 minutes in centrifuge at +40C. The supernatant was separated and used for 
further experiments. 
Protein concentration was determined using bicinchoninic acid (BCA) protein assay 
prior to western blot to ensure equal protein loading. This method is based on the BCA 
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ability to react with complexes between coppers ions and proteins to produce a 
molybdenum/tungsten blue product. Briefly, when copper ions from copper sulphate 
(CuSO4) are added to protein, Cu2+ is reduced to cuprous cation (Cu1+). BCA then reacts 
with Cu1+ and the purple-coloured reaction product is formed by the chelation of two BCA 
molecules with one molecule of Cu1+. BCA/Cu1+ complex is water soluble and can be 
quantitatively read on a 96 plate reader with a filter set at 562 nm. 
 
 
 
 
Protein standards were prepared using bovine serum albumin (BSA) in order to 
create standard curve, plotting relative light absorbance versus protein concentration. 96 
plate reader was programmed to develop the standard curve and determine protein 
concentration. 
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Figure 2. Standard curve with protein concentrations 
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2.5.2 Western Blot Protocol 
 
Cell lysis was performed in radio-immune precipitation assay (RIPA) buffer (50 mM 
Tris pH7.6, 150 mM sodium chloride, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, 
10 mM sodium fluoride, 1 mM sodium ortho-vanadate and 1:100 Calbiochem protease 
inhibitor cocktail set 1) and protein concentration determined using BCA/CuSO4 assay as 
described above. 40 µg of protein per well was resolved by 4-12% gradient Bis-Tris gel 
electrophoresis (Invitrogen, UK) alongside PageRuler pre-stained protein ladder 
(Fermentas, UK); proteins were transferred to nitrocellulose membranes (Millipore, UK). 
The membranes were blocked for 1 hour in 5% BSA in TTBS and probed with primary 
antibodies, diluted in 3% BSA/TTBS: anti-phospho SrcY419 (1:10000), anti-total Src 
(1:10000 Cell Signaling Technologies, UK), anti-phospho FAKY397 (1:10000), anti-
phospho FAK861 (1:10000 Biosource, Belgium), anti-total FAK (1:10000 BD Biosciences, 
UK), anti-phospho PaxillinY118 (1:1000 Biosource , Belgium), anti-total Paxillin ( 1:10000 
BD Biosciences, UK) at 40C overnight. Membranes were then incubated with secondary 
antibodies (anti-rabbit 1:5000 or anti-mouse 1:5000, Cell Signalling Technologies) and 
visualized with ECL kit (Amersham, UK). Where necessary, the membranes were stripped 
by incubating with Re-Blot Plus stripping buffer (Chemicon, UK) before re-probing with 
other antibodies including anti-αTubulin (1:8000 Santa Cruz, USA) to confirm equal 
protein loading. 
 
2.6 Steroid Exposure and Withdrawal 
 
This experiment was conducted to determine the effect of exposure and withdrawal 
of androgens on SFK activity in prostate cancer cell lines. Charcoal-stripped foetal calf 
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serum, known to contain negligible concentration of androgens, at the same time providing 
the necessary growth factors, was used as a model of hormone deprivation. LNCaP and 
LNCaP-SDM cells were seeded in standard culture media at a density of 1x106 per 9 cm 
dish and allowed to attach overnight. The following day, the cells were washed twice in 
PBS and the medium was changed. Each cell line was exposed to three types of media: 
serum-free medium, steroid depleted medium containing 10% charcoal-stripped serum and 
medium containing 10% full foetal calf serum. After 60 hours, which allows for the 
metabolism of intracellular steroid hormones, cell lysates were prepared and western blot 
analysis performed as described above. The membranes were probed with anti-phospho 
SrcY419 (1:10000) and, after stripping, re-probed with anti-total Src (1:10000 Cell 
Signaling Technologies, UK) and anti-αTubulin (1:8000 Santa Cruz, USA)  to confirm 
equal protein loading. 
 
2.7 Src Inhibitor Exposure 
 
LNCaP and LNCaP-SDM cells were seeded at a density of 1x106 per 9 cm Petri dish 
and cultured using standard culture media until 80% confluent and then treated overnight 
with a range of dasatinib concentrations. Cell lysates were prepared and western blot 
analysis performed as described above. The membranes were probed with anti-phospho 
SrcY419 (1:10000), anti-total Src (1:10000 Cell Signaling Technologies, UK), anti-phospho 
FAKY397 (1:10000), anti-phospho FAKY861 (1:10000 Biosourse, Belgium), anti-total FAK 
(1:10000 BD Biosciences, UK). Dasatinib was provided by Bristol Myers Squibb and 
made up as 10 mM stock in dimethyl sulfoxide (DMSO). Once the minimal concentration 
that inhibited Src activity was determined, the cells were treated with the range of 
dasatinib concentrations.  
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2.8 Immunoprecipitation 
 
Immunoprecipitation method is based on the interaction between the antibody and 
the protein, antibody-protein complex formation, the separation of the complex by 
immunoglobulin (Ig), which reacts with the antibody and subsequent analysis by Western 
Blot. In this experiment, IgG agarose beads were used to provide solid phase support for 
immunoprecipitation. Cell lysates were prepared as described in previous sections and 
samples containing 500 µg of protein in 500 µl incubated with anti-total Lyn (1:50 BD 
Biosciences) or anti-total Src (1:100 Cancer Research UK) at 40C overnight. Then, anti-
mouse IgG agarose beads (Sigma, UK) were added to the samples (20 µl per sample) and 
further incubated for 1 hour at 40C. Agarose beads were separated from supernatant by 
pelleting in centrifuge at 10000 rpm for 3 min and washed 3 times in lysis buffer. After 
adding sample buffer and loading dye, immune complexes, released by heating the 
samples at 950C for 5 min, were analysed as per western blot protocol with anti-phospho 
SrcY419 antibody (1:10000 Cell Signaling Technologies). 
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2.9 Migration Assay 
 
2.9.1 Random Migration 
 
To follow random migration, LNCaP and LNCaP-SDM cells were plated at a low 
density (5x104) on glass-bottomed 6-well plates (Iwaki, Japan), allowed to attach overnight 
and then treated with increasing concentrations of dasatinib, diluted in standard culture 
media. Migration was monitored by video time-lapse microscopy for 24 hours using a 
Zeiss Axiovert S100 microscope with x20 objective powered by AQM Advance software 
(Kinetic Imaging, UK). To quantify the ability of the cells to spread on glass surface and 
the effect of dasatinib on cell spreading, the protrusions produced by the cells in each field 
was counted and the number of protrusions per cell was plotted in a column graph. 
 
2.9.2 Wound Healing 
 
Wound healing assay was carried out to investigate the ability of prostate cancer 
cells to migrate into a denuded area in the presence or absence of dasatinib. LNCaP and 
LNCaP-SDM cells were plated at a density of 1x106 cells per well of a glass-bottomed six-
well plate (Iwaki, Japan). The following day, the wounds through the confluent cells 
monolayer were made using a fine pipette tip, three wound per well. The medium was then 
replaced with standard for each cell line culture medium containing increasing 
concentrations of dasatinib.  The assay was performed over 24 hours with images taken 
from 3 fields per each well every 30 minutes using a Zeiss Axiovert S100 microscope at 
x20 magnification.  Cell migration was measured by subtraction of the distance between 
the edge of the wound at time 0 and 24 hours using ImageJ software. 
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2.10 Proliferation Assay 
 
Proliferation was assessed using the WST-1 assay (Chemicon, UK) as per 
manufactures instructions. The assay is based on the enzymatic cleavage of the tetrazolium 
salt WST-1 to a water-soluble formazan dye by cellular mitochondrial dehydrogenases. 
Overall activity of mitochondrial dehydrogenases increases proportionally to the number 
of viable cells. This leads to the increase in tetrazolium salt conversion to formazan dye, 
which correlates directly to the number of metabolically active cells. Following the 
addition of the reagent to the cell culture, the colour intensity changes over time and this 
can be measured by light absorbance using multiwell spectrophotometer at 450 nm. 
Plotting the absorbance level against time produces a parabolic curve, indicating that after 
a period of time a constant increase is reached. Measurements are taken at this point, 
although the cells could be incubated for longer if higher sensitivity is required. 
 
 
 
 Figure 3. Cleavage of WST-1 to formazan 
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Cells were seeded in 96 well plates at a density 5x103 cells per well in standard 
culture media, allowed to attach overnight and the following day treated with increasing 
concentrations of dasatinib, DMSO was added to the control well. The assay was 
performed at 48, 72 and 96 hours by adding 10 µL of WST-1 reagent prior diluted in 
Electro Coupling Solution (ECS) to each well. The optical absorbance level was measured 
after 2 hours incubation at 370C using a 96 well microplate reader at 450 nm with 
reference wavelength 600 nm. The measurements were made from 4 readings in each 
condition and the experiment was repeated 3 times with consistent results. 
To study the effect of androgens on proliferation in the presence of dasatinib, LNCaP 
and LNCaP-SDM cells were plated in standard culture media for 24 hours after which 
LNCaP cells were placed in the steroid depleted medium containing 10% charcoal stripped 
fetal calf serum and LNCaP-SDM cells in RPMI1640 supplemented with 10% full fetal 
calf serum. WST-1 assay was performed at 48, 72 and 96 hours as described above. 
 
2.11 Statistical Analysis 
 
Statistical analysis was performed using Microsoft Excel and the SPSS statistical 
package (version 15.0). Small changes in protein expression between paired ASPC and 
CRPC tumours could be due to random errors in the assessment of histoscores.  To 
identify individual patients in whom there was strong evidence of a genuine rise or fall in 
protein expression, it was required that the change in expression exceeded a threshold 
equal to two standard deviations of the inter-observer difference for that protein.  This 
threshold was chosen because, if there was in reality no difference in protein expression 
between ASPC and CRPC tumours in a given patient, there would be only a 5% 
probability of an apparent difference being observed that exceeded the threshold due to 
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random variation.  This assumes that the random variation between two different observers 
assessing the same tumour is of a similar magnitude to the random variation that would 
affect a single observer assessing two different tumours with the same level of protein 
expression. Changes in protein expression in individual patients that exceeded this 
threshold were termed significant. Wilcoxon Signed Rank Tests were used to compare 
expression between ASPC and CRPC tumours. Survival analysis including time to relapse, 
time to death from relapse and overall survival was conducted using the Kaplan-Meier 
method and curves were compared with the log-rank test. 
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RESULTS 
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3.1 Cohort Description 
 
Clinical data, recorded for each patient (Table 1) included age (median 70, inter 
quartile range (IQR) 66-73), PSA at diagnosis (median 23.2 ng/ml, IQR 4.6-35.6), PSA at 
relapse (median 10 ng/ml, IQR 4-11), Gleason grade at diagnosis (median 7, IQR 4-9) and 
Gleason grade at relapse (median 8, IQR 6-10).  All patients developed biochemical 
relapse (median time to relapse 2.53 years, IQR 1.57-4.43 years).  At last follow-up, 34 
patients had died of prostate cancer and 12 patients had died of other causes, median 
follow up was 8.3 years and inter quartile range was 5.2-9.1 years.  Following diagnosis, 
10 % (5/50) of patients underwent surgical orchidectomy and 90% (45/50) received LHRH 
analogue initially and then anti-androgen therapy in addition.  Following biochemical 
relapse 64% (32/50) patients received radiotherapy, no patients in the current cohort 
received taxane therapy. 
 
Features Median Value Inter-Quartile Range (IQR) 
Age 70 years 66-73 
PSA at Diagnosis 23.2 ng/ml 4.6-35.6 
PSA at Relapse 10 ng/ml 4-11 
Gleason Grade at Diagnosis 7 4-9 
Gleason Grade at Relapse 8 6-10 
Time to Relapse 2.53 years 1.57-4.43 
Follow-up Time 8.3 years 5.2-9.1 
 
Table 1. Main features of patients’ cohort. 
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Table 2. Relationship between main features of the cohort and survival. 
 
Features 
Time to relapse, 
P value 
Time to death from 
relapse, P value 
Disease-specific 
survival, P value 
Age 0.809 0.137 0.434 
PSA at Diagnosis 0.063 0.568 0.664 
PSA at Relapse N/A 0.953 0.045 
Gleason Grade at 
Diagnosis 
0.473 0.026 0.013 
Gleason Grade at 
Relapse 
N/A 0.890 0.781 
Mets at Diagnosis 0.182 0.013 0.002 
Mets at Relapse N/A 0.001 0.012 
 
 
In the table above, survival analysis presented according to the main features of the 
cohort. There was significant association between the presence of metastatic disease and 
survival. Gleason grade at diagnosis had an impact on time to death from relapse and 
disease-specific survival, although it did not influence time to relapse. Age and PSA at 
diagnosis did not demonstrate any relationship with survival characteristics and only PSA 
at relapse was associated with reduction in disease-specific survival. 
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3.2 Immunohistochemistry 
 
In order to determine the level of Src, Lyn and Fgr expression and activation in the 
transition from ASPC to CRPC we used one hundred paraffin embedded prostate tissue 
sections taken from fifty patients with prostate cancer who underwent hormone-
deprivation therapy and subsequently developed hormone relapse. Due to tissue 
heterogeneity, full prostate tissue sections were stained using antibodies against total Src, 
Lyn, Fgr and phospho SrcY419 representing an active form of SFKs and phospho SrcY527, a 
marker suggestive of inactive Src. The sections were double scored and ICCCs were 
calculated for each protein at cytoplasm and membrane. From the table below it is evident 
that ICCCs, determined for each protein, were consistently above level of 0.7, classed as 
excellent. Scatter graphs and Bland-Altman plots were used to confirm that there was no 
observer bias when the sections were immunohostoscored. 
 
Cellular 
Locations 
pSrcY419 pSrcY527 Total Src Fgr Lyn 
Cytoplasm 0.94 0.89 0.88 0.91 0.88 
Membrane 0.92 0.95 0.93 0.87 0.83 
Nucleus N/A N/A N/A 0.78 0.84 
 
Table 3. ICCC determined for each protein. 
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Figure 1. Scatter graphs and Bland-Altman plots for cytoplasmic pSrcY419 based on 
inter-observer variation. The range and distribution of scores confirmes appropriate 
inter-observer correlation. 
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Figure 2. Scatter graphs and Bland-Altman plots for membrane pSrcY419 based on 
inter-observer variation. The range and distribution of scores confirmes appropriate 
inter-observer correlation. 
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Table 4. SFK protein expression profiles. 
 
Histoscores Number of Patients Antibody 
ASPC CRPC Increase Fall No change 
P value 
pSrcY419       
cytoplasm 45 (18.75-80) 70(40-90) 13(26%) 3(6%) 34(68%) 0.035 
membrane 20(0-60) 50(0-90) 14(28%) 3(6%) 33(66%) 0.017 
pSrcY527       
cytoplasm 80(50-112.5) 50(20-90) 6(12%) 18(36%) 26(52%) 0.002 
membrane 50(20-80) 20(0-70) 13(26%) 21(42%) 16(32%) 0.101 
Total Src       
cytoplasm 130(100-180) 100(80-126.3) 4(8%) 16(32%) 30(60%) 0.009 
membrane 55(20-116.3) 55(30-110) 10(20%) 13(26%) 27(54%) 0.926 
Total Lyn       
cytoplasm 28(5-70) 50(20-80) 17 (34%) 8 (16%) 25 (50%) 0.094 
membrane 38(10-80) 70(35-95) 25 (50%) 6 (12%) 19 (38%) 0.005 
Total Fgr       
cytoplasm 65(39-100) 50(30-78) 8 (16%) 15 (30%) 27 (54%) 0.104 
membrane 95(69-112) 90(63-108) 8 (16%) 14 (28%) 28 (56%) 0.567 
 
 
The sequences surrounding Src autophosphorylation site tyrosine Y419 are highly 
conserved in the majority of SFK and positive staining using this antibody represents 
autophosphorylation not only of Src but also other Src family members.  There was a 
significant increase in overall pSrcY419 immunostaining in the transition from ASPC to 
CRPC, more intense cytoplasm and membrane staining was observed in CRPC samples 
compared to ASPC. In addition, although the majority of matched specimens on an 
individual patient basis showed no change in expression of phospho SrcY419 in the 
transition from ASPC to CRPC, a subgroup of patients did have tumours that exhibited a 
rise in expression as determined by the weighted histoscore technique (Figure 1).   
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                         ASPC                                                                  CRPC 
              
 
Figure 3. Examples of pSrcY419 immunostaining in specimens from a patient 
exhibiting an increase in Src activity in the transition from ASPC to CRPC. 
Magnification x400. 
 
Small changes in protein expression between paired ASPC and CRPC tumours could 
be due to random errors in the assessment of histoscores, therefore the mathematic method 
as described in the methods statistical analysis section was employed for selection of 
patients with genuine rises in expression. Changes in protein expression in individual 
patients that exceeded this threshold were termed an increase in expression.  Using this 
method 13(26%) and 14(28%) patients were noted to have an increase in expression of 
activated SFKs (phospho SrcY419) in the cytoplasm and membrane respectively (Table 2). 
In addition, there was an increase in overall Lyn membrane immunostaining in the 
transition from ASPC to CRPC (Figure 1); more intense cytoplasm and membrane staining 
was observed in CRPC samples compared to ASPC (although only membrane staining 
reached significance).  No change in expression was observed for Fgr and, interestingly, 
expression of total Src and phospho SrcY527in the cytoplasm fell significantly after the 
patients developed hormone relapse whereas the membrane staining did not change. 
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3.2.1 SFK Expression and Clinical Parameters 
 
Following the diagnosis of prostate cancer, the majority of the patients (46 or 92%) 
had bone scans, in 8 patients (16%) it was positive, implying the presence of bone 
metastases, and in 38(76%) it was negative. After the development of CRPC, the patients, 
who had positive bone scans at diagnosis and no bone scan after relapse were considered 
as having bone metastases as well as those who had negative bone scans at diagnosis and 
positive scans at relapse (26(52%)).  The membranes in the tumour samples taken from 
patients with CRPC stained more intensely with the anti-phospho SrcY419 antibody if there 
was evidence of bone metastases (P=0.011). No significant correlation was observed 
between the presence of bone metastases and cytoplasmic staining with antibodies against 
phospho SrcY419, phospho SrcY527, total Src, Fgr or Lyn. 
The cohort was then further subdivided into groups according to Gleason grade at 
diagnosis and PSA value at relapse, important prognostic criteria in patients with prostate 
cancer. High or low PSA at relapse were not associated with IHC histoscores and only 
expression of cytoplasmic Lyn in the hormone refractory tumours was associated with 
Gleason grade (p=0.029). 
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Figure 4. Correlation of total Lyn histoscore with Gleason score in CRPC samples. 
There was a significant positive correlation between cytoplasmic total Lyn histoscores 
and Gleason grade of prostate cancer speciments. 
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3.2.2 Survival Analysis 
 
Use of paired prostate cancer specimens taken from patients prior to commencement 
of hormone manipulation therapy and after androgen escape, made it possible to correlate 
IHC scores of each individual patient with various survival parameters including time from 
diagnosis to biochemical relapse, time from relapse to death and overall survival. 
Statistical analysis revealed that a subset of patients, who had an increase in SFK activity 
(phospho SrcY419 expression) at the membrane in the transition from ASPC to CRPC, had 
a significantly shorter time to relapse, median time from diagnosis to hormone escape in 
this subgroup of patients was 1.86(IQR 1.36-2.47) years compared to 2.98(IQR 1.93-4.63) 
years for those who had decreased membrane signal or no change (P=0.005).  
 
Figure 5. Kaplan-Meier survival curve plotting the time from prostate cancer 
diagnosis to hormone relapse. The patients, who had an increase in Src activity 
developed hormone escape significantly earlier than those who had a decrease or no 
change in  Src activation. 
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Furthermore, the time from biochemical relapse to death was also reduced: 1.14 
(IQR 0.58-2.15) years versus 1.87 (IQR 1.1-1.86) years (P=0.011).   
 
Figure 6. Kaplan-Meier survival curve plotting the time from prostate cancer relapse 
to death. The patients, who had an increase in Src activity had significantly shorter 
time from hormone relapse to death than those who had a decrease or no change. 
 
Therefore, the combination of reduced time to relapse combined with reduced time 
to death following relapse resulted in a significant reduction in overall survival, median 
survival for those with an increase in membrane phospho SrcY419 expression was 
2.91(IQR 2.42-4.92) years compared to 6.33(IQR 4.15-7.27) years for those patients with 
tumours that had a decrease or no change in phospho SrcY419 expression (P<0.0001).  
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Figure 7. Kaplan-Meier survival curve plotting the time from prostate cancer 
diagnosis to death. The patients, who had a decrease or no change in Src kinase 
activity lived significantly longer than those who had an increase in Src activity.  
 
 However, when multivariate Cox regression analysis was performed for the patients 
with an increase in SFK activity taking into account the presence of metastases at relapse 
and Gleason score, SFK activity was noted to be independently significant only for the 
time from relapse to death (P=0.018) and overall survival (P=0.01).  
No association with the time to relapse or survival was observed for Fgr, total Src 
and phospho SrcY527, however an increase in membrane Lyn expression was associated 
with a shorter time to relapse (P=0.022).  Median time from diagnosis to hormone escape 
in this subgroup of patients was 2.29(IQR 1.78-2.79) years compared to 3.2(2.45-3.99) 
years in those who had a decreased membrane signal or no change. This was also observed 
for an increase in cytoplasmic Lyn expression, median time from diagnosis to hormone 
escape in this subgroup of patients was 2.41(IQR 2.01-2.73) years compared to 3.2(IQR 
1.98-4.45) years in those who had decreased membrane signal or no change (P=0.040). 
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However, multivariate Cox regression analysis demonstrated that increase in Lyn 
expression was not independently significant when the presence of metastases at relapse 
and Gleason score were considered. No association with time from biochemical relapse to 
death or overall survival were observed. 
 
3.3 LNCaP and LNCaP-SDM Cell Lines 
3.3.1 Androgen Stimulation 
 
LNCaP cell line is an established model of hormone sensitive prostate cancer; 
whereas LNCaP-SDM cell line has been developed using parental LNCaP cells by gradual 
reduction of androgens in the medium, thus simulating androgen withdrawal during 
hormone deprivation therapy. In order to confirm androgen sensitivity of these cell lines, 
androgen stimulation experiment was conducted. Both cell lines were exposed to the 
medium containing charcoal stripped foetal calf serum, full foetal calf serum and a range 
of DHT concentration (0.1 nM, 1 nM, 10 nM, 100 nM). Cells were counted following 48, 
72 and 96 hours (Figure 6).  
Cell count showed that the cell line reacted differently to the DHT exposure. LNCaP 
cells displayed dose-dependent increase in the number of cells at 48 hours time point. At 
72 and 96 hours intervals, this pattern continued with the exception of cells exposed to 100 
nM of DHT the number of which did not increase, probably due to DHT toxicity. In 
contrast, the number LNCaP-SDM cells did not increase in response to DHT, there was 
slight decrease in cell numbers with increasing DHT concentration after 96 hours. Thus, it 
was concluded that LNCaP and LNCaP-SDM cells represent good in-vitro models of 
androgen sensitive and castration resistant prostate cancers respectively. 
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                                   LNCaP                                  LNCaP-SDM 
             
             
             
 
 
Figure 8. LNCaP (left column) and LNCaP-SDM (right column) cells counted 
following the exposure to DHT.  Medium containing charcoal stripped and full foetal 
calf sera used for controls. The cells were harvested after 48, 72 and 96 hours after 
the exposure to DHT. The column bars represent the relative numbers of the cells per 
condition.  Error bars represent standard deviation from 4 counts. 
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3.3.2 Steroid exposure and withdrawal 
 
In order to assess the effect of androgen stimulation and withdrawal on Src kinase 
activity, both cell lines were exposed to various culture media including serum-free 
medium, medium containing dextran charcoal-stripped foetal calf serum (steroid depleted 
medium) and full foetal calf serum.  SFK activity in LNCaP cells, experiencing acute 
androgen withdrawal in steroid depleted medium was reduced to the same degree as in the 
cells that were serum starved.  In LNCaP-SDM cells, routinely cultured in charcoal-
stripped serum, long-term androgen deprivation resulted in higher basal level of SFK 
activity compared to LNCaP cells in equivalent culture conditions. When deprived of 
growth factors in serum-free medium LNCaP-SDM cells displayed a further reduction in 
SFK activity, whereas treatment of these cells with full foetal calf serum containing 
physiological amount of androgens, increased SFK activity, although it did not reach the 
level observed in parental LNCaP cells. 
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Figure 9. Steroid exposure and withdrawal experiment. Both cell lines were exposed 
to various culture media, including serum starvation (SS), steroid depleted medium 
(SDM) and medium containing full foetal calf serum (FM). Src kinase activity was 
estimated by western blot analysis. The cells in full medium, containing physiological 
concentrations of androgens exhibited the highest Src activity, whereas hormonal 
deprivation as well as serum starvation dramatically reduced activity of Src kinase. 
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3.4 Inhibition of SFK Activity In Vitro 
3.4.1 Inhibition of SFK Activity and Downstream Markers 
 
Dasatinib was used to investigate the effects of Src inhibition on LNCaP and 
LNCaP-SDM cells. Treatment of LNCaP and LNCaP-SDM cells with dasatinib resulted in 
a dose-dependent reduction of SFK activity using the autophosphorylation of Src at 
tyrosine Y419 as a marker of activation. Complete inhibition of SFK activity in LNCaP 
cells was seen at 50 nM. SFK activity was also suppressed in LNCaP-SDM cells, although 
complete inhibition was achieved at slightly higher concentrations (75 nM). Interestingly, 
in LNCaP-SDM cells increasing the dose of dasatinib resulted in an increase in total Src. 
 FAK phosphorylation on tyrosine Y861 (Src-dependent phosphorylation site) was 
also inhibited by treatment with dasatinib in both cell lines in a dose-dependent manner 
while the levels of phospho FAKY397 (Src-independent autophosphorylation site) and total 
FAK remained unchanged (Figure 10 and 11). We investigated whether inhibition of Src 
kinase activity would result in downstream inhibition of Paxillin, which is used in various 
studies as a biomarker of effectiveness of SFK inhibitor therapy. Our experiments have 
demonstrated that in both LNCaP and LNCaP-SDM cells there was no significant 
reduction in Src-dependent phosphorylation of pPaxillinY118 (Figure 12).  
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Figure 10. LNCaP and cells were exposed to increasing concentrations of dasatinib. 
Western blot results confirmed Src suppression with 10 nM dasatinib and higher. 
Src-dependent phosphorylation site pFAKY861 was also inhibited, whereas 
pFAKY397, which is Src-independent was not affected. 
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Figure 11. LNCaP-SDM cells were exposed to increasing concentrations of dasatinib. 
Western blot results confirmed Src suppression with 25 nM dasatinib and higher. 
Src-dependent phosphorylation site pFAKY861 was also inhibited, whereas 
pFAKY397, which is Src-independent was not affected. 
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Figure 12. LNCaP and LNCaP-SDM cells were treated with various concentration of 
dasatinib and Western blot performed to find out whether inhibition Src kinase 
activity would result in reduction of Src-dependent phosphorylation of PaxillinY118. 
This experiment demonstrated that there was no inhibition of pPaxillinY118 in both 
LNCaP and LNCaP-SDM cell lines.
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3.4.2 Study of Src and Lyn activity 
 
Due to cross-reactivity of anti-phospho SrcY419 antibody in the majority of SFK it was 
necessary to immunoprecipitate Src and Lyn to study the effect of dasatinib on kinase 
activity in individual family members.  Therefore, initially it was necessary to extract each 
protein from the lysates of the LNCaP and LNCaP-SDM cells treated with dasatinib, by 
conjugating them with anti-total Src or Lyn antibodies. The extracted proteins were then 
processed using Western blot technique and the membranes probed with anti-phopsho 
SrcY419 antibody that would detect both Src kinase and Lyn kinase activity. Dasatinib 
inhibited Lyn autophosphorylation in both LNCaP and LNCaP-SDM cells at equivalent 
concentrations (Fig. 3D).  Higher concentrations were necessary to inhibit Src 
autophoshorylation in the LNCaP-SDM cells. 
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Figure 13. Inhibition of Src and Lyn activity studied separately by 
immunoprecipitation due to cross-reactivity of anti-pSrcY419 anitboby in SFK. Src 
and Lyn were initially extracted from the lysates of LNCaP and LNCaP-SDM cells 
exposed to dasatinib in different concentrations, with anti-total Src and Lyn 
antibodies and then processed using Western blot technique. The membranes were 
then probed with anti-pSrcY419 antibody that detected both Src and Lyn kinase 
activity. 
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3.5 Inhibition of Cell Migration by Dasatinib 
3.5.1 Protrusion Dynamics 
 
Dasatinib treatment of prostate cancer cells altered microscopic appearances of the 
cells, resulting in cell rounding and the loss of cell protrusions. The changes, observed 
using light microscope, were dose dependent and correlated with the results of western 
blot, showing inhibition of Src and FAK activity. Interestingly, morphological changes in 
LNCaP cells were more pronounced when compared to LNCaP-SDM cells.The dramatic 
changes in cells shape could not be attributed to dasatinib toxicity as the cells, esp. LNCaP 
continued to proliferate at the same rate in each condition. 
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Figure 14. Morphological changes in LNCaP and LNCaP-SDM cells observed after 
dasatinib treatment overnight in standard culture media using increasing 
concentrations of the inhibitor. There was dramatic loss of cells shape with the 
appearences corresponding to the changes in SFK activity. 
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Microphotographs in figure 13 reveal alteration in the shapes of cells treated with 
dasatinib, resulting in cell rounding and loss of protrusions. Development of cell 
protrusions is an important phase in cell migration and proliferation. Protrusions serve as 
propulsion mechanism, allowing the cells to penetrate through extracellular milieu and, in 
case of the cells growing in the laboratory, attach and spread on the underlying surface as 
well as develop cell-cell contacts. Preventing the cells from developing protrusions, 
dasatinib inhibited cell spreading. This was observed and quantified over period of 24 
hours using time lapse microscopy.   
 
128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Protrusion formation in LNCaP-SDM cells treated with dasatinib. 
LNCaP-SDM cells ceded on glass surface and treated with increasing consentrations 
of dasatinib. Protrusion count was performed for every cell in the field and the final 
number was the average number of protrusion per cell. Protrusions count result 
represents the average of 3 fields in each condition.  
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3.5.2 Wound healing 
 
Time lapse video microscopy was employed to investigate the effect of dasatinib on 
LNCaP and LNCaP-SDM cell migration into a denuded area using a wound healing assay. 
The cells were ceded and the wound were made through a confluent monolayer, 3 wound 
per field. The results represent an average of 3 measurements per each condition and the 
experiment repeated 3 times with consistent results. 
 Both, LNCaP and LNCaP-SDM cells exhibited a similar dose-dependent reduction 
in migration when treated with increasing concentrations of dasatinib for 48 hours (Figure 
15).  Column graphs, representing quatification analysis are included (Figure 16). The 
measurements reflect the difference in the distance between the edges of wounds at the 
beginning of the experiment and at the end. Thus, the difference was greater for the cells 
that were untreated or treated with low concentrations of dasatinib as they travelled more, 
while the difference between the edges of wounds for the cells treated with high 
concentrations of dasatinib was minimal. 
LNCaP cells cultured in full medium, containing foetal calf serum were noted to 
have long protrusions, whereas the protrusions, produced by LNCaP-SDM cells when kept 
in androgen depleted medium, rarely exceeded the length of the body of the cell. 
Interestingly, when cultured in the medium containing physiological concentrations of 
androgens (foetal calf serum), the number of LNCaP-SDM cells forming long protrusions 
significantly increased. 
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        LNCaP                LNCaP-SDM 
                                                          
                                                       
                                                          
                                                             
                                                                                          
                                                      
Figure 16. Migration of prostate cancer cells into denuded areas. LNCaP and 
LNCaP-SDM cells were treated with dasatinib and the wound were made through 
the confluent monolayer. The cells then migrated into the denuded space as 
represented by the control at the beginning of the experiment and after 48 hours. 
Microphotographs of treated cells at the end of the experiment are presented. 
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Figure 17. Quantitative assessment of wound healing assay. Column bars 
represent the difference between the distance between wound edges at the 
beginning of the experiment and after 48 hours. The cells in control wells 
migrated further than the cells treated with dasatinib. Error bars represent 
standard deviation from 3 measurements in each condition. 
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3.6 Inhibition of Cell Proliferation by Dasatinib 
 
Growth of hormone sensitive LNCaP cells is driven mostly by androgens while 
hormone refractory LNCaP-SDM cells are thought to depend on growth factors 
transmitting oncogenic signals via tyrosine kinases.  Treatment with dasatinib inhibited 
proliferation of hormone-refractory LNCaP-SDM cells in a dose-dependent manner (IC50 
500 nM) at concentrations corresponding to inhibition of SFK activity.  Proliferation of 
hormone sensitive LNCaP cells was not significantly inhibited by dasatinib even at 
concentrations up to 10 µM. Interestingly, introduction of androgens to the steroid 
depleted medium, used for routine culture of LNCaP-SDM cells, did not rescue 
proliferation suppressed by dasatinib.  In addition, treatment of LNCaP cells experiencing 
acute androgen withdrawal in steroid depleted medium did result in further inhibition of 
proliferation although this was observed at concentrations of dasatinib higher than 10 µM 
and, therefore, this effect was thought to be non-specific. 
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Figure 18. Effect of dasatinib on cell proliferation as determined by WST-1 assay. 
LNCaP and LNCaP-SDM cells were treated with a range of dasatinib concentrations. 
This graph represents the results of WST-1 assay performed at 96 hour time point. 
Optical absorbance level is proportional to the number of metabolically active cells 
and presented here as the percentage of the control, with the control being 100%. 
There was no significant reduction in proliferation of LNCaP cells whereas the 
proliferation of LNCaP-SDM cells was significantly reduced with dasatinib 
concentrations 75 nM and higher. Error bars represent the standard deviation from 
4 measurements in each condition. 
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Introduction 
 
Prostate cancer is the most common cancer in men and second leading cause of 
cancer-related deaths in the western world (29). Patients with locally advanced or 
metastatic prostate cancer are mostly prescribed castration therapy in the form of LHRH 
agonists, anti-androgens or surgical orchidectomy. Inevitably, despite the treatment, the 
disease progresses towards hormone resistant state, leaving the patients and the clinicians 
few viable options. Palliative methods usually consist of pain relief by means of analgesia 
and palliative radiotherapy to the areas of painful bone metastases, bisphosphonates and 
radioisotopes. Application of systemic chemotherapy in patients with hormone refractory 
prostate cancer has proved disappointing, only taxane-based therapy has shown clinically 
significant improvement in survival, palliation of symptoms and improvement in quality of 
life (195). 
Urgent requirement for further research into molecular mechanisms underlying the 
development of CRPC has been highlighted by the lack of progress in the treatment of the 
disease. In a recent systematic review of clinical trials investigating the effect of 
chemotherapy in prostate cancer, published by Cochrane Collaboration Project (196), the 
authors recommended further research in molecular and genetic complexities of the 
disease as a way to improve the outcomes. Numerous controversies, resulting in difficulty 
interpreting and comparing the trials, stem from heterogeneity in patient populations as 
well as individual cases. Therefore, stratification of patients into well defined groups by 
selecting individuals according to positive biomarkers, for example, is considered 
important in order to increase the likelihood of successful treatment (197).  
Malignancies are characterised by up-regulation of multiple signalling pathways, 
allowing the cancer cells to evolve and adapt to constantly changing microenvironment. 
Defining key elements, driving intracellular signalling can potentially result in the 
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development of inhibiting strategies, although it is unlikely that single agents would have 
‘magic bullet’-like impact. Combining the agents, used to target multiple molecular 
cascades or using novel small molecule inhibitors with conventional cytotoxic drugs and 
hormone deprivation therapy could be a way forward (150). Although multiple potential 
targets have been identified, certain molecules, including SFK, are more promising in 
terms of inhibiting potential. This is due to convenient position of SFK on the map of 
signalling pathways, being involved in the extensive cross-talk and regulating multiple 
intracellular events. 
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4.1 Correlation of SFK Activity with Clinical Parameters 
 
4.1.1 Immunohistochemistry 
 
Despite exponential growth in number of laboratory tests available to clinicians over 
the last 50 years, histopathology remains the gold standard when it comes to decision 
making in surgical oncology and pathology. Interpretation of histological data is based 
primarily on tissue morphology and, therefore, inherently it is a subjective process.  In 
order to add objectivity, immunohistochemistry (IHC) has initially been used to 
complement morphological appearances of the tissue with molecular information. More 
recently, IHC has become standard in predicting and evaluating response to novel 
molecular based targeted therapies (198). In breast cancer, for example, IHC is used to 
determine ER status in order to select the patients who should receive tamoxifen. IHC has 
been crucial in discovery that HER-2 status could predict resistance to systemic therapies 
and HER-2 positivity is associated with increased mortality and higher rate of recurrence 
(199). Moreover, targeting HER-2 with humanised monoclonal antibodies, such as 
Trastuzumab (Herceptin; Genentech, CA) or small molecule dual HER-1/HER-2 inhibitor 
Lapatinib (Tykerb, GlaxoSmithKline, PA) improves outcomes in context of metastatic 
disease and adjuvant therapy (200;201).  
Since the discovery of IHC by Coons and Jones, who established immunofluorescent 
method to detect bacteria, the technique has become standard in diagnostic pathology and 
experimental biology. In our laboratory, IHC has been employed extensively to study 
cancer cell signalling using paraffin-embedded tissue sections (112;202;203). The 
technique typically starts with antigen retrieval with the goal to unmask the antigen, 
hidden by formalin cross-links. Although several methods of antigen retrieval exist, for the 
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purpose of SFK staining, when optimising the procedure it was established that it is best 
performed in pressure cooker with tissue slides immersed in citrate buffer. The next step 
involved application of primary antibody and it was determined that best results were 
achieved when exposure to antibody for total Src was limited to 1 hour, whereas it was 
necessary to incubate the tissue section with phospho-specific antibodies overnight. This 
followed by exposure to secondary antibody, depending on species in which primary 
antibody was raised. It was possible to achieve consistent immunostaining with the range 
of colours allowing necessary quantification. 
Molecular quantification methods have been in existence for several decades. These 
techniques include reverse transcriptase polymerase chain reaction (RT-PCR) for 
quantification of nucleic acids, and antibody-based methods for protein quantification, e.g. 
enzyme-linked immunosorbent assay (ELISA). A major disadvantage of these methods is 
the requirement for tissue destruction in order to quantify specific biomolecule, with 
complete loss of valuable spatial information. In case of SFK, it was essential to 
differentiate cytoplasmic from membrane immunostaining due to the fact that inactive 
SFK are positioned mostly in peri-nuclear area, whereas SFK activation is associated with 
the transfer of the proteins through the cytoplasm to the membrane. In fact, most important 
findings were made when analysing membrane immunostaining. 
Interpretation of IHC results has been the subject of extensive debates, particularly 
following introduction of IHC-based tests into routine medical practice. The need to 
standardise IHC reading has been highlighted recently, when it was found that in up to 
20% of HER-2 tests, performed in breast cancer patients may be inaccurate, with resulting 
clinical implications for the treatment and prognosis (204). Inter-observer variability, 
therefore, represents a major issue affecting the accuracy of results with clinical and 
scientific implications. Although IHC is interpreted subjectively by pathologists or 
experimental biologists, it is possible to produce an objective and continuous system or 
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scale to measure protein expression. The technique of weighted histoscore, employed in 
this study, provides the possibility to quantify protein expression by means of continuous 
variable (205).  
Regardless of tumour type or size, if the tissue sections are scored by two 
independent appropriately trained observers, it is possible to achieve consistency and 
reproducibility, reducing the need for dual scoring down to 10% of samples without 
sacrificing the accuracy. The quality and standards of inter-observer variation can be 
determined by interclass correlation coefficient (ICCC), which is expressed as the variance 
between subjects relative to the sum of the variance components for subjects, observers 
and random error (205). ICCC represents a step further from HSCORE (206) and Allred 
(207) criteria that attempted initially to produce more continuous scale than binary 
positive-negative end point or a 3- to 4-point scale. While the lower acceptable threshold is 
a matter of debate, the ICCC level of >0.9 is considered to be excellent (205).  In this 
study, it was possible to achieve ICCC score higher than 0.9, producing sufficient quality 
of data interpretation. 
 
4.1.2 Tissue Sampling 
 
Another possible issue affecting variability of IHC results relates to tissue 
heterogeneity, stemming from processing methods (fixation methods, extent of fixation 
and validation of reagents) as well as true biological heterogeneity. While the former 
received much attention in the literature, very little is known about the latter. It is 
important to consider that prostatic adenocarcinoma represents a heterogeneous group of 
neoplasms with broad spectrum of pathologic and molecular characteristics and variable 
natural history of the disease (208).  Therefore, when tracking the changes in the tissue 
throughout the course of the disease, it is preferable to study the samples that are related to 
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each other as closely as possible. As there is significant geographical and racial variation 
in the rates and aggressiveness of prostate cancers (29), the individuals should ideally be of 
the same race and living in the same area. Although it is not always possible, the series of 
tissue samples should be from the same individuals and this should contribute to the 
reduction of variability. 
The subjects, recruited for this study were all Caucasian males from Central Scotland 
region. Fifty patients were selected according to stringent criteria and, therefore, only one 
patient was deemed suitable out of twenty considered .  The selected patients received no 
prior treatment and following the diagnosis, were given castration therapy, resulting in 
biochemical response as represented by a significant reduction in PSA. Thus, the tissue 
samples taken prior to the treatment being administered could be considered as hormone 
naïve. The patients had regular PSA measurements allowing to determine when they 
reached PSA nadir and when PSA levels started to rise, the patient were considered as 
having hormone relapse. The second tissue sample was taken following hormone relapse 
when the patients developed bladder outflow obstruction and underwent channel TURP. 
This second tissue sample, therefore, represented castration-resistant prostate cancer. 
Accordingly, having two sets of prostatic tissue samples, taken from the same individual 
prior to castration therapy and following hormone relapse, made it possible to track the 
changes in SFK protein expression and activation in each individual. 
While having matched paired tissue samples provided an advantage in comparing the 
protein expression and activation before and after hormone relapse, by including the 
patients all of whom underwent channel TURP may have introduced selection bias. At the 
time of writing there were no publications, studying patients with CRPC undergoing 
channel TURP. Sehgal et al. reported 42 patients with advanced prostate cancer requiring 
channel TURP, although the status of hormone sensitivity was not commented upon (209). 
The authors noted that the patients requiring channel TURP had higher Gleason grade than 
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the patients, who presented with acute urinary retention and had successful trial of voiding. 
In another study of 19 patients with advanced prostate cancer, 67 % had high grade 
(Gleason grade 8-10) prostate cancer, whereas only 22.7% of prostate cancer patients, 
undergoing TURP for bladder outflow obstruction, prior to diagnosis being established, 
had high grade disease (210). It is also possible to argue that the patients, who had 
operative interventions may have had less co-morbidities, than those, who developed 
symptoms of bladder outflow obstruction and were treated conservatively, with indwelling 
catheter for example. At present, prostate biopsy is not performed routinely in patients 
with CRPC and, therefore, channel TURP represents the only source of prostate tissue in 
patients with CRPC. 
 
4.1.3 Analysis of SFK Immunostaining 
 
Analysing matched paired prostate cancer tissue samples, taken from patients prior 
to hormone deprivation therapy being administered and after hormone relapse, made it 
possible to correlate molecular changes, occurring in the tissue as the patients developed 
hormone resistance, with various clinical parameters. Despite the fact that a wealth of 
information on SFK status in vitro in prostate cancer cell lines is available and the 
commencement of clinical trials of SFK inhibitors in CRPC, there are no studies of SFK 
expression and activation in clinical samples in relation to clinical data, including survival. 
Goldenberg-Furmanov et al.  reported immunohistochemical analysis of total Lyn 
expression in prostatic epithelium in human prostate cancer samples and in prostate cancer 
metastases (15). The authors noted that Lyn immunostaining in prostate cancer cells was at 
least as intense as in adjacent normal prostatic epithelium. In addition, when prostate 
cancers were showing two Gleason grade patterns, Lyn expression tended to be higher in 
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less differentiated regions. Another SFK member Fyn was also found to be overexpressed 
in prostate cancer as compared to normal prostatic epithelium (17). 
Although the expression of total SFK proteins in cancer is probably important, it is 
SFK activation that is thought to be a key element in oncogenesis (13). Phosphorylation of 
tyrosine Y419 of Src kinase domain and its equivalent in other family members is regarded 
as a reliable marker of SFK activation and, therefore, application of phospho-specific 
antibodies can be used to define SFK activation status in human prostate cancer tissue 
(211). Paronetto et al. described the use of anti-phospho SrcY419 antibody to stain prostatic 
tissue and found that in 4 patients with advanced prostate cancer (Gleason grade 7-9), 
membrane immunostaining of cancer cells was more intense than that of normal prostatic 
epithelium. In another publication on the role of AR phosphorylation in prostate cancer, 
pSrcY419 immunostaining was performed using prostate cancer tissue microarrays (50). 
The prostate cancer tissue taken from the patients with hormone-refractory disease stained 
more intensely, when compared to hormone-naïve tumours and benign prostatic 
hyperplasia.  
In this study, IHC was performed using antibodies against total Src, total Lyn, total 
Fgr, phospho SrcY419 and phospho SrcY530 (marker of Src inactivation). SrcY419 
autophosphorylation site is highly conserved in all SFK members and, therefore, it is not 
possible to say activation of which SFK member is prevalent in stained tissue due to cross-
reactivity. In the future, commercially produced antibodies could be used to distinguish the 
role of activation of different SFK members. SFK immunostaining was almost exclusively 
confined to prostate cancer epithelium with very little staining of stroma cells. Comparing 
the staining of pre-treatment prostate cancer tissue to the tissue taken following hormone 
relapse, subgroups of patients were identified, in whom there was a significant change. In a 
subgroup of 14 patients (24%), there was a significant increase membrane anti-phospho 
SrcY419 immunostaining (p=0.017), in the transition from ASPC to CRPC. Survival 
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analysis showed that these patients had shorter tome to relapse (p=0.005), shorter time to 
death from relapse (p=0.011), which resulted in shorter overall survival (p<0.0001). This is 
the first study to demonstrate the correlation between the increase in membrane pSrcY419 
immunostaining and survival in prostate cancer patients. 
Separating cancer patients according to positive biomarkers is becoming common in 
oncology, where the treatment is increasingly tailored according to individual tumour 
profile. The patients with advanced breast cancer are now routinely tested for HER-2 
status of their breast tumours to identify those who are likely to benefit from HER-2 
targeted therapy. It is thought that approximately 20-30% of patients with advanced breast 
cancer are found HER-2 positive and receive HER-2 inhibitor trastuzimab (198). As SFK 
inhibitors are now in clinical trials for CRPC, it may be beneficial to test prostate cancer 
patients in order to identify those with the increase in SFK activity in prostatic epithelium. 
Defining this subgroup may increase the quality of statistical data (enrichment method), 
which ultimately could be translated into clinical practice. 
Much attention in literature has been given to the role of Src in normal function of 
bone cells and bone re-modelling in metastatic disease (179). Preponderance of metastases 
in prostate cancer to the bones is well known and represents a major source of morbidity. 
Targeting key molecules, participating in formation and development of bone metastases 
in prostate cancer may provide clinicians with novel therapies that could be used at 
different stages, including localised prostate cancer in neo-adjuvant context as well as 
progressive and advanced stage, where limiting growth of metastatic deposits may help to 
palliate the symptoms (180). We found that in patients with CRPC, prostate tumour 
samples taken from those who had metastatic disease stained more intensely with anti-
phospho SrcY419 antibody than those who did not have evidence of bone metastases 
(p=0.011). This is probably due to up-regulation in SFK activity leading to more 
aggressive and motile phenotype, promoting detachment of cancer cells and metastatic 
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spread. Thus, selecting the patients at an earlier stage may provide the opportunity to target 
SFK activation and potentially prevent or reduce the chance of developing secondary bone 
tumours.   
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4.2 Cell Line Model of Castration Resistance 
 
Attempts to establish in vitro cultures of prostatic carcinoma have been ongoing 
since early 20th century. First attempts were successful in so far as the development of 
primary tissue cultures that only lasted short term. It was not until 1970s when Fraley et al. 
described a prostatic cell line, although it was later found to be cross-contaminant of HeLa 
cells (212). Over the following years, establishment of stable continuous cell lines has 
proved particularly difficult in prostate cancer. To date, there are over 30 cell lines used in 
research settings and the number continues to grow although, most in vitro studies 
employed the three earliest established prostate cancer cell lines: LNCaP (213), PC-3 (214) 
and DU-145 (215). Interestingly, all three cell lines have been derived from metastatic 
sites: LNCaP from lymph node, PC-3 from bone and DU-145 from brain. While LNCaP 
cell line is considered to be hormone responsive and, therefore, represents a model of 
ASPC, PC-3 and DU-145 are androgen independent. Thus, PC-3 and DU-145 cell lines 
have been used in laboratory experiments as in vitro models of castration resistance. 
Potential drawback of the use of PC-3 and DU-145 cell lines in studies of molecular 
mechanisms of the development of CRPC in general and the role of SFK in prostate cancer 
in particular, is the fact that none of these cell lines express AR (216). Increasingly, it is 
thought that AR plays a major role in the progression of prostate cancer to castration 
resistance. Studies of clinical tumour samples have shown that the majority of CRPC 
samples express functional AR and that the tissue concentrations of PSA and other 
androgen-responsive genes increase in the setting of castration-resistant tumour growth 
(217). In context of SFK signalling in prostate cancer, AR has been demonstrated to create 
complexes with Src, activating Src-dependent pathways and stimulating growth of CRPC 
(40). It is possible to transfect PC-3 cells with AR in order to investigate the action of anti-
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androgens on various cell functions, although taking a hormone sensitive cell line and 
attempting to develop castration resistance by withdrawing the androgens would probably 
produce more physiologically relevant results. 
Recently, in vitro studies and in animal experiments, scientists have increasingly 
been using derivatives of LNCaP cell line expressing functional AR with the ability to 
progress in androgen depleted conditions. Thalmann et al. described the development of 
C4-2 cell line by inoculating LNCaP cells into male athymic nude mice, castrating the 
mice and maintaining the resultant cell line in the castrated host (218). This model was 
mimicking closely the natural history of prostate cancer with the ability to develop both 
lymph node and bone metastases in vivo and, therefore, was suggested for further studies 
on molecular mechanisms of CRPC. This cell line was later found to overexpress Src 
protein and the treatment with Src inhibitor PP2 was demonstrated to increase apoptosis 
(219). Furthermore, inhibiting Src resulted in reduced AR transactivation and subsequent 
recruitment to AR target genes, reduced growth and invasion. Another related cell line C4-
2B was used to produce metastatic animal model of prostate cancer by injecting the cells 
into tibiae of SCID mice. Application of SFK inhibitor dasatinib alone or in combination 
with docetaxel was effective in lowering sacrifice serum PSA and increasing bone mineral 
density in the tumour sites (220). 
In this study, we used LNCaP-SDM cell line, a variant of LNCaP cell line that was 
developed by gradual withdrawal of androgens from culture medium and maintained in the 
medium supplemented by charcoal stripped foetal calf serum, containing significantly 
reduced concentration of androgens. Androgen stimulation experiment demonstrated that 
LNCaP cells displayed dose-dependent reaction to DHT stimulation, whereas LNCaP-
SDM cells did not increase proliferation when DHT was added to steroid-depleted 
medium. There was increase in proliferation of LNCaP cells with the concentrations of 
DHT up to 10 nM, although the cells stimulated by 100 nM DHT demonstrated reduced 
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growth probably due to DHT toxicity. Therefore, LNCaP-SDM cell line, developed by 
mimicking androgen withdrawal during hormone deprivation therapy, represented a good 
model of castration-resistant prostate cancer.  
We then investigated whether androgen deprivation would affect SFK activity by 
placing the cells in various media with or without androgens. Androgen withdrawal led to 
dramatic reduction in SFK activity in both cell lines, especially in androgen-sensitive 
LNCaP cells. This is probably due SFK in the presence of androgens being activated by 
AR via complex formation and SFK intramolecular displacement. Although this effect was 
more pronounced in LNCaP cells, androgen stimulation also led to the increase in SFK 
activity in LNCaP-SDM cell line, suggesting continuous importance of AR signalling in 
CRPC and cross-talk with SFK. In LNCaP cells, significant reduction in SFK activity 
when being placed in androgen-depleted medium, equalled to serum starvation further 
underlying the importance of AR signalling for SFK-dependent pathways. 
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4.3 Role of SFK Activation in Prostate Cancer 
 
4.3.1 Biomarkers of SFK Activation 
 
With increasing use of SFK inhibitors in clinical practice, it is imperative that 
reliable biomarkers of SFK activation are developed. Phospho-specific antibodies, raised 
against activated enzymes have proved essential when studying molecular signalling 
pathways. These antibodies can be applied in clinical settings in order to determine the 
concentrations of inhibitors necessary to achieve the desired clinical effect. This is 
especially important in context of SFK inhibitors, given that it is Src activation rather than 
total expression, which is thought to drive oncogenic signalling (13). Identification of Src 
autophosphorylation site tyrosine Y419 provided a reliable read-out of Src activity due to 
correlation of its level with kinase activity of the enzyme (169). Upon Src activation, 
multiple downstream substrates become phosphorylated and, therefore, these could be also 
used as biomarkers. Among them, Src-dependent phosphorylation sites on paxillin 
phosphorylated at tyrosine Y118, FAK phosphorylated at tyrosine Y861 and p130cas 
phosphorylated at tyrosine Y410 have been previously suggested (158;169).  
In this study, we used anti-phospho SrcY419 as a biomarker of Src activity in clinical 
samples. In vitro experiments have demonstrated that Src kinase activity was reduced in 
dose-dependent manner, when LNCaP and LNCaP-SDM cells were exposed to SFK 
inhibitor dasatinib. As expected, dasatinib treatment led to the decrease in Src-dependent 
phosphorylation of FAK at tyrosine Y861 and autophosphorylation of FAK at tyrosine Y397, 
which is Src-independent, did not change. Therefore, both pSrcY419 and pFAKY861 could 
potentially represent biomarkers of SFK inhibition. Dose-dependent inhibition of Src and 
FAK activity was further correlated with microscopic appearances of the cells as dasatinib 
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induced dramatic morphological changes, resulting in protrusion withdrawal and cell 
rounding. Interestingly, our experiments showed that phosphorylation of paxillin at 
tyrosine Y118 was not affected by dasatinib and, therefore, the role of paxillin activation in 
prostate cancer would need to be further elucidated. 
Phospho-sequences surrounding Src tyrosine Y419 and its equivalents in other SFK 
are very similar and, therefore, it is not possible to distinguish between various SFK 
members, unless SFK members are investigated separately. This could be done in both 
tissue cultures and clinical samples, although important spacial information would be lost 
due to the necessity of tissue destruction. It has previously been suggested that various 
SFK members may have different roles in the development of prostate cancer and its 
progression to castration resistance. Knockout of Src by siRNA revealed that Src 
suppression impacted mostly on cell migration, whereas inhibition of Lyn resulted in the 
reduction of proliferation (18). Dasatinib has previously been demonstrated to inhibit both 
Src and Lyn using in vitro kinase assay (158). Immunoprecipitation experiments, 
performed in this study have shown that kinase activity of both Src and Lyn were inhibited 
by dasatinib. Presently, it is not known which SFK member is responsible for the 
functional outcome of SFK suppression as this data will only be available when phospho-
specific antibodies are developed against each SFK member. 
 
4.3.2 SFK Role in Cell Proliferation 
 
Despite considerable evidence implicating SFK in cellular proliferation, questions 
remain whether SFK activation or elevated expression has any effect on the actual tumour 
growth in solid malignancies. In studies involving colon and bladder cancer cell lines, 
increased expression of constitutively active or kinase-defective mutants of Src did not 
affect cell proliferation (221;222), whereas other studies demonstrated inhibition of 
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proliferation, when expression of Src was reduced by antisense approach (223). In prostate 
cancer, the proliferation of hormone-sensitive tumours is mostly driven by androgens and, 
therefore, the focus of investigations on the role of SFK in cellular proliferation has been 
on castration-resistant tumours. Extensive cross-talk of SFK with growth factor receptors 
and GPCRs may imply certain SFK involvement in proliferative cascades, although it is 
not clear whether SFK expression or activation is essential in stimulating CRPC growth. 
 Conflicting results from the studies based on molecular manipulation stem from the 
lack of specificity small molecule inhibitors often display. PP1 and PP2 for example, 
pyrazolopyrimidine-based competitive inhibitors of ATP binding have been extensively 
used in tissue culture, including prostate cancer cell lines, to study the cellular features of 
Src inhibition (224). Pyrazolo-pyrimidine compounds have been applied in proliferation 
and migration studies in order to elicit the effect of Src inhibition in prostate cancer cells 
stimulated with various growth factors (43;46;91). These chemicals are proven, however, 
to inhibit other tyrosine kinases including PDGF, stem cells factor receptor c-Kit, tyrosine 
kinase Ret etc. with an in vitro IC50 below the concentration used in these experiments 
(225-227). Recently developed SI35 and SI40  pyrazolo(3, 4-d) pyrimidines were effective 
in reducing EGF stimulated PC-3 cells proliferation at concentrations 5 µM and higher, 
whereas much lower doses of the inhibitors were used to elicit the reduction in cell 
adhesion and migration (162). 
Dasatinib, SFK inhibitor used in this study, has been demonstrated to inhibit 
proliferation of PC-3 cells at low nanomolar concentrations (157). Park et al. showed that 
dasatinib significantly inhibited proliferation of LNCaP and a highly tumorigenic variant 
of PC-3 cells at concentrations above 100 nM (18). As the concentration of dasatinib 
required to inhibit Src kinase activity was 10 nM and Lyn activity 100 nM, the authors 
concluded that inhibition of proliferation was primarily due to inhibition of Lyn. However, 
at concentrations 100 nM and above, dasatinib is known to inhibit multiple targets and, 
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therefore, this effect could be non-specific (157). Although we are in agreement with Park 
et al. that Src kinase activity in LNCaP cells is inhibited by dasatinib at concentration 10 
nM and above, we did not find that the suppression of Lyn kinase required higher 
concentrations of the inhibitor. Furthermore, no evidence of the inhibition of LNCaP cell 
proliferation was demonstrated, whereas proliferation of LNCaP-SDM cells was inhibited 
by dasatinib at concentrations corresponding to the suppressed SFK activity. 
Suppression of proliferation by SFK inhibitors at concentrations correlating to the 
inhibition of SFK activity have only been shown in a small subset of prostate cancer cell 
lines (157;220). Similarly, in vitro studies in other solid tumours, including colon cancer, 
head and neck cancer, non-small cell lung cancer, the majority of cell lines were 
insensitive to the treatment with dasatinib at concentrations required to inhibit Src activity. 
Moreover, dasatinib at higher concentrations has been shown to inhibit proliferation of 
SYF-/- cells, lacking the expression of all main Src family members, confirming the 
possibility of non-specific action (169). Thus, it appears that certain cell lines involve SFK 
in their proliferative signalling pathways, whereas others employ different mechanisms. 
Inhibition of proliferation of LNCaP-SDM cells, demonstrated in this study is probably 
due to the higher dependence of castration-resistant tumours on tyrosine kinases, whereas 
hormone-sensitive LNCaP cells mostly rely on androgens for their growth. 
 
4.3.3 SFK Role in Cell Migration 
 
Unlike the role of SFK in proliferation that is still debatable, there is consensus 
among scientists that SFK are essential in promoting motility of cancer cells (13). SFK 
activation influences cancerogenesis from early stages in the process involving normal 
epithelial cells acquiring highly motile phenotype (EMT) and later, during the course of 
the disease stimulating local invasion and metastatic spread. In prostate cancer, SFK play a 
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major role in cell motility in both androgen-sensitive and castration-resistant disease. In 
this study, SFK inhibitor dasatinib suppressed migration of LNCaP and LNCaP-SDM cell 
lines using concentrations required to inhibit SFK activity. Dasatinib treatment resulted in 
major changes in the shape of the cells with cell rounding and loss of protrusions. When 
the cells were placed on a flat surface, dasatinib affected cell spreading in a dose-
dependent manner. 
Regulation of the motility of cancer cells requires activation of Src in complexes 
with FAK and subsequent recruitment of multiple signalling proteins (87). Extracellular 
signals, emanating from integrins and receptor tyrosine kinases stimulate Src/FAK 
complex formation, which is an essential element in the regulation of focal adhesions turn-
over and changes in tumour cells leading to EMT. Inhibiting Src kinase activity may 
prevents FAK phosphorylation and downstream signalling, disrupting protein complexes 
clustering in focal adhesions and adherens junctions. In vitro experiments have 
consistently shown that SFK inhibitors reduce Src-dependent phosphorylation of FAK on 
tyrosine pFAKY861, while phosphorylation of Src-independent pFAKY397 is not affected 
(18;158). Our data has also confirmed that treatment of LNCaP and LNCaP-SDM cells 
with small nanomolar concentrations of dasatinib reduced pFAKY861 phosphorylation in 
dose-dependent manner. 
Inhibition of Src and downstream proteins may result in dramatic changes in cancer 
cells’ behaviour. Recchia et al. demonstrated that PC-3 cells treated with Src inhibitor 
were unable to spread on flat surface. This was due to inability by cancer cells to produce 
amoeboid protrusions necessary for subsequent migration (16). Using time-lapse 
microscopy, we showed that the cells treated with small doses of dasatinib developed 
fewer protrusions when seeded on glass surface as compared to controls, whereas the cells 
treated with higher doses did not form protrusions at all. Dasatinib treatment also resulted 
in the cells that had already spread to become rounded although, as expected the cell-cell 
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contacts were maintained. Interestingly, treatment of androgen-sensitive LNCaP cells 
resulted in more profound changes, while castration-resistant LNCaP-SDM cells 
maintained their shape better. 
Inability of prostate cancer cells to produce protrusions following dasatinib treatment 
resulted in limited migratory capacity as confirmed by wound healing assay in this study. 
This is due to the cells that unable to develop protrusions and, therefore, lacking the power 
of propulsion that propagate the body of the cells in the direction of movement. SFK 
inhibitors also affect invasive properties of the cells due to downregualtion of MMP-9 
activity, which is FAK-dependent. MMP-9 and TIMP-1 and -2 are necessary for 
degradation of protein constituencies of extra-cellular matrix, allowing cancer cells to 
invade neighbouring structures (16). Importantly, the concentrations of SFK inhibitors 
used to elicit inhibition of migration have consistently been found much lower than 
concentrations, required to suppress proliferation and, generally, correlate well with 
inhibition of SFK activity probably suggesting this effect is Src-specific (162).  
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4.4 SFK Inhibitors in Clinical Trials and Practice 
 
Development of molecular biology and our knowledge of how cancers behave 
stimulated the discovery of multiple potential targeting agents, many of which have never 
progressed beyond clinical trials. Despite unprecedented investment into the field, there 
has been meagre progress with only several drugs officially approved for the use in solid 
malignancies. Delay in adjusting the design of clinical trials to the complexities of new 
molecular targeted agents has been recently highlighted as a potential reason why so many 
substances that have been found promising in pre-clinical stages, have not been 
demonstrated to be effective in clinical trials (228). 
Historically, histological diagnosis with staging has been the principal factor guiding 
the clinicians and the researchers in providing specific treatment or defining the eligibility 
for the clinical trials. This is despite the fact that the many cancers that histologically seem 
equal, possess different genetic and molecular make-up and have varying natural history. 
In prostate cancer, the implications of biological heterogeneity have led to the search of 
new approaches to the management of the disease, and yet the molecular differences are 
still not taken into account when selecting the patients for the clinical trials. In a letter to 
the editor in the Journal of Clinical Oncology, Michael Castro has written that the previous 
researchers’ habit of presuming homogeneity in the sample group represented the 
simpleton’s error from the vantage point of today’s molecular biology (228). The author 
went further to question whether it is ethical to treat the patients, enrolling into the clinical 
trial with the inhibitors of the enzymes their cancers do not express. 
Molecular heterogeneity implies that in some cases only a small subset of cancers 
would be sensitive to a specific targeted therapy. Therefore, inevitably the treatment might 
fail to show the efficacy in a conventional randomised clinical trial simply due to the 
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diversity of the studied population. As a result, the promising drug might never find its 
way into the clinical practice, denying the patients with the sensitive malignancy a 
potentially beneficial treatment. In an elegant statistical experiment, Betensky et al. have 
demonstrated that in genetically different groups of patients entering a hypothetical clinical 
trial comparing chemo-radiotherapy with radiotherapy alone, failure to take into account 
the genetic heterogeneity will in most cases result in the phase III trial being underpowered 
and too small (229). This is possibly due to several reasons, including enrichment of phase 
II trials with treatment-sensitive individuals, followed by dilution or reversal of positive 
effect in responders by non-responders. 
In the present study, we identified a subgroup of 28% of patients in whom there was 
significant association between SFK activation and overall survival (p<0.0001). Using 
pSrcY419 as a biomarker, identifying these patients may prove beneficial in patients’ 
selection for specific targeting with SFK inhibitors. Obtaining the cancer tissue represents 
potential difficulty as the patients with CRPC do not routinely undergo prostatic biopsy, 
unless they develop the symptoms and signs of bladder outflow obstruction and the tissue 
is harvested by means of channel TURP. However, contemporary methods increasingly 
incorporate the prostate biopsy into management protocols in order to determine the 
progression of the disease, e.g. during active surveillance. Thus, in the future, the 
development of molecular targeted therapies may necessitate the biopsy of the prostate in 
CRPC patients with a view to identify molecular and genetic changes, guiding the 
treatment and defining the prognosis. 
Several SFK inhibitors are now in phase I and phase II clinical trials for the patients 
with CRPC (155;188-192). Traditionally, there has been an assumption that the dose of 
cytotoxic drug is proportional to their anti-tumour activity and, therefore, in order to get 
maximum benefit in phase I trials the dose is escalated until it reached the level causing an 
acceptable toxicity.  However, with new biological agents, this may not be necessary as the 
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aim of the treatment is to inhibit the specific enzyme. Indeed, the concentrations of 
dasatinib, SFK inhibitor used in this study, required to completely inhibit Src kinase 
activity was in the region of 10-25 nM, and this has also been demonstrated by others 
(18;158). Pharmacodynamics of the drug can be monitored by measuring the concentration 
of the inhibitor in blood and by studying the level of pSrcY419 in peripheral blood cells as a 
surrogate target tissue that has been shown to correlate with intra-tumour Src activity 
(170). 
It has been suggested that the design of phase II trials of molecular targeted agents 
should be altered. Enrichment of phase II trials may need to be more robust, selecting 
groups of patients who are likely to respond and, perhaps, carrying this further into phase 
III trials (230). Important considerations would have to be given to the mechanism of 
action of particular drugs when selecting response criteria. In the recently reported results 
of phase I/II clinical trials of dasatinib alone and in combination with docetaxel in patients 
with CRPC, the researchers used PSA response as a main endpoint, although PSA level 
mostly reflects the bulk of the disease, which may not necessarily be affected by the drugs 
(231;232). Given that it is not clear whether SFK inhibitors in general and dasatinib in 
particular would reduce prostate cancer cell proliferation and, therefore, actual tumour 
growth, more weight perhaps should be given to the appearances of new metastatic 
deposits. We have demonstrated that pSrcY419 immunostaining in CRPC specimens 
correlated with the presence of bone metastatic disease. It would of interest to look into the 
development of metastases in other organs, i.e. lymph nodes, liver etc. 
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4.5 Conclusion 
 
There is considerable evidence implicating SFK in the development of prostate 
cancer in its progression to castration resistance. However, translational studies 
investigating the significance of increased SFK expression and activation in clinical 
samples are lacking. To date this is first study to address the question whether existing in 
vitro data and the results of animal experiments would be relevant in clinical settings. It 
appears that in a subgroup of prostate cancer patients, SFK activation is associated with 
reduced survival and the presence of bone metastases correlated with increased SFK 
activity. Although the SFK role in tumour cell growth is debatable, in our experiments the 
treatment of castration-resistant cell line LNCaP-SDM with dasatinib resulted in inhibition 
of proliferation. Moreover, both androgen-sensitive LNCaP and castration-resistant 
LNCaP-SDM cell lines exhibited reduced migration upon exposure to dasatinib, implying 
potential use of the inhibitor as an anti-metastatic agent. 
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APPENDIX 1 
 
Examples of immunostaining for total Src, pSrcY527, total Lyn and total Fgr 
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